InSiGHT

11th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours

4 - 7 March 2026 | Dusit Thani Laguna Singapore

www.insight2026.org

E-PROGRAMME BOOK

Partners: JGHFoundation, Familial Cancer

Organised By: ICaN Asia, Singapore Society of Oncology

Supported By: IAP International Academy of Pathology Singapore Division, SCRS

Held In: Singapore Passion Made Possible

Managed By: kenes group singapore

Navigating through InSiGHT 2026



Exhibiting Companies	Booth Number
Amazon Web Services Singapore Private Limited	C02
Gene Solutions Singapore Pte Ltd	B03
illumina Singapore Genomics Pte Ltd	B02
MSD Pharma (Singapore) Pte Ltd	A01
NovogeneAIT Genomics Singapore Pte Ltd	A02
Oxford Nanopore Technologies Singapore Pte Ltd	C01
PacBio	B01
Promega Pte Ltd	C03
Twist Bioscience Inc.	A03

CONTENTS

Welcome Message

Welcome to Singapore! Selamat Datang! 欢迎! வருக வருக!

On behalf of InSiGHT, we are delighted to welcome you to the InSiGHT meeting in Singapore, taking place from 4 – 7 March 2026. This landmark event is jointly organised by the Singapore Society of Oncology (SSO) and the Inherited Cancer Network (ICaN) Asia, marks a significant milestone in advancing hereditary gastrointestinal cancers in our region.

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) is a global, multidisciplinary scientific organisation dedicated to advancing the care of patients and families affected by hereditary gastrointestinal cancers. Over the past five decades, collaborative research led by InSiGHT have driven groundbreaking discoveries in conditions such as Lynch syndrome, Familial Adenomatous Polyposis (FAP), and Hereditary Diffuse Gastric Cancer (HDGC), ultimately improving clinical outcomes worldwide.

Singapore, alongside its regional partners, has been at the forefront of precision medicine, investing in infrastructure and expanding access to genetic services for patients and families. This conference represents a unique opportunity to bring together surgeons, clinicians, researchers, geneticists, genetic counsellors, nurses, policymakers, caregivers, and patients from across Asia. Through collaborative education, research presentation, and shared clinical experience, we hope to better understand the unique challenges in our region and chart the path forward for education, research, and clinical innovation in hereditary gastrointestinal cancers.

As a vibrant, multicultural hub, Singapore is the perfect meeting point for this exchange of knowledge and expertise. Beyond the scientific program, we hope you take the opportunity to experience the rich heritage, dynamic food scene, and warm hospitality that define our city.

We extend our deepest gratitude to our supporting partners — the Singapore Society of Colorectal Surgeons (SCRS), the Gastroenterological Society of Singapore (GESS), and the International Academy of Pathology (IAP) Singapore Division and Heapato Pancreato Biliary Association — for making this conference possible.

On behalf of the InSiGHT organising committee, we warmly welcome you and look forward to fruitful days of scientific exchange.

Joanne Ngeow
Chair-Elect, International Society for GI Hereditary Tumors (InSiGHT)

About The International Society for Gastrointestinal Hereditary Tumours (InSiGHT)

Our History

InSiGHT was formed in 2005 by the merger of the Leeds Castle Polyposis Group (LCPG) and the International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). In 2010 it became an incorporated charity in England and Wales.

In 1985 a meeting of experts with an interest in polyposis syndromes was organised at Leeds Castle, an historic castle in Kent, UK. In 1989 the LCPG was formally established.

The ICG-HNPCC was conceived in Jerusalem, Israel, in 1989. In 1990 the first formal meeting of the ICG-HNPCC was held in Amsterdam, The Netherlands.

In 1997 the first joint meeting of LCPG and ICG-HNPCC took place in Noordwijk, The Netherlands. At the third joint meeting in Venice, Italy in 2001 it was agreed that the ICG-HNPCC should merge with the LCPG to form a new society – InSiGHT.

What we do

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) is an international multidisciplinary, scientific organisation. Our mission is to improve the quality of care of patients and families with any hereditary condition resulting in gastrointestinal tumours.

We do this by

- Educating physicians and other healthcare professionals in the molecular genetics and clinical management of gastrointestinal hereditary tumour syndromes
- Housing and curating the most comprehensive database of DNA variants that contribute to gastrointestinal cancer
- Supported by a committee of world leading experts, systematically assigning pathogenicity to variants in the genes predisposing to gastrointestinal cancer
- Encouraging research into all aspects of gastrointestinal hereditary tumour syndromes
- Providing a forum for the presentation of data, discussion of controversial areas involved in the care of patients and their families, and facilitation of collaborative studies
- Assisting institutions and individuals interested in beginning or maintaining a registry for families with gastrointestinal hereditary tumour syndromes

About Organising Societies

ICaN Asia
INHERITED CANCERS NETWORK ASIA

ICaN Asia

The Inherited Cancers Network Asia (ICaN Asia) is a non-profit organization founded in 2025 with a dedicated mission to improve health outcomes for individuals affected by hereditary cancers in the Asia-Pacific region.

To achieve this, ICaN Asia is establishing a real-time registry that will serve as an essential resource for healthcare professionals, driving better care coordination and informed treatment decisions. Our efforts are centered around several core objectives:

Improving Care Coordination

We aim to identify and address gaps in patient management, ensuring individuals receive the seamless care they deserve from diagnosis through treatment.

Expanding Access to Clinical Trials

ICaN Asia is committed to ensuring that individuals in the Asia-Pacific region have access to the latest treatments and preventative clinical trials, broadening the opportunity for life-changing therapies.

Promoting Genomic Medicine Research

We actively support pan-Asian research that spans from basic science to multi-center clinical trials, enhancing our understanding of hereditary cancers and advancing targeted treatments.

Empowering Patients & Raising Awareness

Our mission includes engaging and empowering patients, increasing awareness of hereditary cancers, and promoting early detection. By educating communities, we encourage a proactive approach to managing inherited cancer risks.

ICaN Asia is dedicated to making a lasting impact on the lives of individuals affected by hereditary cancers.

Through collaboration, knowledge-sharing, and advocating for patients, we strive to create tangible improvements in healthcare outcomes across the region.

About Organising Societies

Singapore Society of Oncology

The Singapore Society of Oncology (SSO), founded in 1981, is a professional medical organisation for all Singapore healthcare professionals who treat and manage cancer patients. The aim of the SSO is to provide an active platform to promote the practice of oncology through education, research, collaborations and partnerships with allied local, regional and international organisations.

The SSO is committed to providing continued medical education (CME) and other opportunities for the cancer specialist community to further enhance their knowledge, skills and expertise in the rapidly evolving practice of oncology. Where relevant or necessary, the SSO will also represent the views of the society and its members in public forums and debates.

Our Mission

- To advance the knowledge & practice of medicine in the field of oncology especially in the prevention, recognition & treatment of oncological diseases in this country
- To promote research in the Republic of Singapore in oncology
- To organise regular scientific discussions and practical demonstrations on subjects related to the prevention, recognition and treatment in oncology
- To contribute actively to medical and health education at all levels

About Organising Societies

Society of Colorectal Surgeons (Singapore)
www.scrs.org.sg

Society of Colorectal Surgeons Singapore

- To develop the speciality of colorectal surgery and to promote its awareness to a high standard and good standing in Singapore
- To be the professional body which sets standards and guidelines for members in the management of surgical colorectal disease in Singapore
- To participate in national programs for the prevention and screening of colorectal cancer or other significant colorectal diseases
- To foster friendship, understanding and collaboration among its members and with international colorectal surgical societies especially those in ASEAN

Gastroenterological Society of Singapore

In the last three decades, GESS has hosted Scientific Meetings (GIHep), Endoscopy Workshops and Postgraduate Courses for doctors and nurses annually. In 1995, GESS collaborated with the American Gastroenterological Association (AGA) to hold its first Asian AGA meeting in Singapore. Since then, GESS has continued to host other successful regional meetings in Gastroenterology and Hepatology, such as the Asian Pacific Digestive Week (APDW) in 2003 and 2011, and the Asian Pacific Association for the Study of the Liver (APASL) Liver Week in 2013.

Our Objectives Are:

- To advance the knowledge and practice of Gastroenterology and Hepatology in Singapore
- To promote research in Gastroenterology and Hepatology
- To promote regional and international collaborations with other Gastroenterological societies
- To organise meetings, seminars and conventions on Gastroenterology, Hepatology and Endoscopy
- To publish educational materials in the field of Gastroenterology and Hepatology

About Organising Societies

Heapato Pancreato Biliary Association

Hepato Pancreato Biliary Association (Singapore) is a professional organisation formed to elevate the standard of care of liver, pancreatic and biliary diseases in Singapore by promoting education, training and research in these areas. The idea of forming a hepatobiliary/pancreatic association in Singapore was first mooted in 2008 by a group of hepatobiliary surgeons following the official formation in the region of the Asian-Pacific Hepato-Pancreato-Billiary Association (A-PHPBA).

International Academy of Pathology Singapore Division

The IAP is dedicated to the advancement of Pathology through educational exchanges worldwide. In order to achieve this mission, the academy will:

Serve as an international pathology organisation that coordinates activities of its divisions and encourages the formation of new divisions where appropriate.

- Convene an international congress each biennium providing educational programs to advance pathology education, research and practice
- Provide access to the highest quality pathology education worldwide through lectures and seminars, educational grants, international congresses and teaching materials - accessible through its Divisions
- Encourage strategic placement of international congresses to promote access to advanced Pathology Education in underserved areas

Local Organising Committee

Joanne Ngeow
Lee Kong Chian School of Medicine,
Nanyang Technological University,
National Cancer Centre,
Singapore

Jon Emery
Lee Kong Chian School of Medicine,
Nanyang Technological University,
Singapore

Lee Ser Yee
Singapore General Hospital,
Singapore

Kieron Lim
Gastroenterological Society of Singapore,
Singapore

Surendra Mantoo
Society of Colorectal Surgeons,
Singapore

Joseph Sung
Lee Kong Chian School of Medicine,
Nanyang Technological University,
Singapore

Patrick Tan
Duke-NUS Medical School,
Singapore

Tan Yu Bin
Singapore General Hospital,
Singapore

Sunny Wong
Lee Kong Chian School of Medicine,
Nanyang Technological University,
Singapore

Yeo Yen Ching
KK Women's and Children's Hospital,
Singapore

Yeoh Khay-Guan
National University of Singapore,
Singapore

Scientific Committee

Francesc Balaguer
Hospital Clinic of Barcelona,
Spain

Daniel Buchanan
University of Melbourne's Centre for Cancer Research,
Australia

Ian Frayling
Cardiff University,
United Kingdom

Marc Greenblatt
The University of Vermont Medical Center,
United States

Mustak Ibn Ayub
Department of Genetic Engineering and Biotechnology, University of Dhaka,
India

Matthew Kalady
The Ohio State University Wexner Medical Centre,
United States

Andrew Latchford
St Mark's National Bowel Hospital
London,
United Kingdom

Brandie Leach
Exact Sciences,
United States

Rashid Lui
GI Genetic and Genomic Clinic at PWH,
Hong Kong SAR

Kevin Monahan
The St Mark's Centre for Familial Intestinal Cancer,
United Kingdom

Finlay Macrae
The Royal Melbourne Hospital,
Australia

Sunny Wong
Lee Kong Chian School of Medicine,
Nanyang Technological University Singapore,
Singapore

Tan Yu Bin
Department of Gastroenterology & Hepatology Singapore General Hospital,
Singapore

Laura Valle
IDIBELL Hereditary Cancer Group,
Spain

General Information

Date
4 - 7 March 2026

Venue
Dusit Thani Laguna Singapore
11 Laguna Golf Green, Singapore 488047
www.dusit.com/dusitthani-laguna-singapore

Complimentary Shuttle Service
InSiGHT 2026 provides daily transport from EXPO MRT Station Exit E (Near to Changi City point)

View schedule here.

4 March
Every 15 minute interval from 08:00 to 08:30

5 & 6 March
Every 15 minute interval from 06:45 to 08:15

7 March
Every 15 minute interval from 06:45 to 08:45

Limousine Service
Limousine Transfer service is available for pick-up from the airport, tailored for any group size and schedule. For more information, please view full details here or email dtlsconcierge@dusit.com to enquire.

Car
- Take Airport Blvd., Exit 1 and PIE to Upper Changi Rd E.
- From Airport Blvd., slight left onto the PIE ramp to Singapore Expo/Tuas/TPE/SLE
- Take exit 2 for Upp Changi Rd East
- Turn left to stay on Upper Changi Rd E
- Turn right at the 1st cross street onto Laguna Golf Green

Car Park
Onsite Parking Available
Car parks is available at Dusit Thani Laguna Singapore; charges apply.

Language
The official language of this Congress is English. All presentations must be in English.

Congress Managed By
Kenes MP Asia Pte Ltd
20 Kallang Avenue, PICO Creative Centre Level 2 Singapore 339411
www.insight2026.org

General Information

Congress Badge

Please note that your Congress badge is personal and non-transferable. You may collect your badge at the Badge Collection Counter.

Name badges must be worn at all times to gain access to all InSiGHT 2026 programmes.

Kindly prepare your E-Ticket (QR Code) or confirmation email to ensure a smooth badge collection process.

Please refer to the table below for badge collection counter opening hours:

Date	Time (Singapore GMT +8)
4 March 2026, Wednesday | Day 1	08:30 – 16:50
5 March 2026, Thursday | Day 2	07:00 – 16:50
6 March 2026, Friday | Day 3	07:00 – 17:40
7 March 2026, Saturday | Day 4	07:30 - 12:30

Your ticket type determines your access to the Main Congress (4 – 7 March 2026).

E-Certificate of Attendance

E-Certificate of attendance will be sent via email 2 weeks after the Congress

Invited Speakers

Aysel Ahadova
Germany

Shen Baiyong
China

Francesc Balaguer
Spain

Daniel Buchanan
Australia

Carol Burke
United States

Sir John Burn
United Kingdom

Giulia Martina Cavestro
Italy

David Church
United Kingdom

Susan Clark
United Kingdom

Evelien Dekker
Netherlands

Ding Peirong
China

Jon Emery
Singapore

Heather Hampel
United States

Megan Hitchens
United States

Matthew Kalady
United States

Maria Katapodi
Switzerland

Sonia Kupfer
United States

Andrew Latchford
United Kingdom

Leow Wei Qiang
Singapore

David Liska
United States

Finlay Macrae
Australia

Ranjit Manchanda
United Kingdom

Kevin J Monahan
United Kingdom

Joanne Ngeow
Singapore

Maartje Nielsen
Netherlands

Jean Christophe Saurin
France

Diane Simeone
United States

Laura Valle
Spain

Chella Van Der Post
Netherlands

Programme

4 March, Wednesday | Main Congress Day 1

Time	Pre-InSiGHT Workshops			
08:30 - 09:00	*Registration*			
09:00 - 12:00	*Laguna Ballroom* **Hereditary GI Cancers Masterclass** Chair: Manasa Karthikeyan, Singapore Faculty: Heather Hampel, United States Megan Hitchins, United States Susan Clark, United Kingdom Sonia Kupfer, United States Francesc Balaguer, Spain	*Albatross & Birdie* **Endoscopy Workshop** Chairs: Tan Yu Bin, Singapore Andrew Latchford, United Kingdom Faculty: Matthew Kalady, United States Evelien Dekker, Netherlands	*Offsite* **Chinatown Walking Tour** **09:00 - 12:30** *(Ticketed)*	*Laguna National Golf Resort Club* **Golf Game** **08:00 - 12:00** (Self-registration and payment via the link provided on Congress website)
Time	**Main Congress Day 1** *Laguna Ballroom*			
12:30 - 14:00	Congress Registration			
14:00 - 14:20	**Welcome Address** Joanne Ngeow, Singapore Gabriel Capellá, Spain			
14:20 - 15:40	**Session 1: Population Genomics and Risk Stratification** Chairs: Susan Clark, United Kingdom Noah Helderman, Netherlands [Y-InSiGHT]			
14:20 - 14:40	**Scaling Up Cancer Screening for Population Health** Kevin Monahan, United Kingdom			
14:40 - 15:00	**Applying Polygenic Risk Scores to Tailor Colorectal Cancer Screening in Primary Care** Jon Emery, Singapore			
15:00 - 15:40	**Abstract Presentations 1** Chairs: Sunny Wong, Singapore | Amalia Nanciu, Germany [Y-InSiGHT] **Improving Colorectal Cancer Risk Prediction in Latinos Using Polygenic Scores and Machine Learning** Luis G Carvajal Carmona, United States **The Familial Cancer Experience in South Africa: A Model for Implementing Genomic Medicine in Developing Countries** Raj Ramesar, South Africa **Lynch Syndrome Re-Defined Through a Universal Germline Genetic Testing Program** Heather Hampel, United States **Improving Hereditary GI Cancer Referral Rates using Electronic Health Records** Andrea Tan Wan Ling, Singapore			
15:40 - 16:10	*Coffee/Tea Break*			
16:10 - 17:30	**Session 2: Health System and Implementation Science** Chairs: Sonia Kupfer, United States Chiang Jianbang, Singapore			
16:10 - 16:30	**Cascade Testing and Family Screening Strategies** Maria Katapodi, Switzerland			
16:30 - 16:50	**EMR Based Carrier Management** Finlay Macrae, Australia			
16:50 - 17:30	**Abstract Presentations 2** Chairs: Toni Seppälä, Finland | Jeanette Yuen, Singapore **Cost-effectiveness of Genetic Testing to Diagnose Lynch Syndrome in Singapore** Sara Tasnim, Singapore **Decision Regret and Willingness to Pay for Cancer Genetic Testing: A Longitudinal Contingent Valuation Study** Agnes Wong, Singapore **Clinical Outcomes and Healthcare Costs in Hereditary Diffuse Gastric Cancer: A European Multicenter Study** Carla Oliveira, Portugal **Feasibility Of Pap-derived Cfdna For Early-detection Of Sporadic And Lynch-Associated Endometrial And Ovarian Cancers** Alicia Latham, United States			
17:30 - 17:45	**Day 1 Adjourn**			
18:00 - 19:30	*The Nest, Laguna* **Welcome Reception**			
20:00 - 22:00	**Y-InSiGHT Padel Game** (Y-InSiGHT Members Only)			

Disclaimer: The programme is accurate as of the time of publication. It is subject to change at the discretion of the Organising Committee without prior notice.

Programme

5 March, Thursday | Main Congress Day 2

07:30 - 08:20	*Laguna Ballroom* **Young InSiGHT Breakfast Session** Chairs: Benjamin Zare, United Kingdom Amalia Nanciu, Germany Noah Helderman, Netherlands	*Albatross & Birdie* **ClinGen Vcep Breakout Session** Chairs: Marc Greenblatt, United States Sharon Plon, United States	*Eagle Boardroom* **Genetic Counsellors' Roundtable** Chairs: Manasa Karthikeyan, Singapore Brandie Leach, United States Marie Met-Domestici, Switzerland
Time	*Laguna Ballroom*		
08:30 - 10:10	**Session 3: Genetics and Molecular Insights in Hereditary Gastrointestinal Tumours** Chairs: Jean Christophe Saurin, France Gloria Chan, Singapore		
08:30 - 08:50	**Tracing Cancer Evolution in Hereditary Gastrointestinal Tumours** Daniel Buchanan, Australia		
08:50 - 09:10	**Novel Genetic Drivers in Familial Colorectal Cancer** Laura Valle, Spain		
09:10 - 10:10	**Abstract Presentations 3** Chairs: Gabriel Capellá, Spain | Grolmusz Vince Kornel, United States [Y-InSiGHT] **Somatic CTNNB1 Mutations as a Positive Predictor of Lynch Syndrome** Aysel Ahadova, Germany **Inflammasome-Related Gene Variant Predisposing to Familial Colorectal Carcinoma** Taina T Nieminen, Finland **Immune Infiltration in Lynch Syndrome Colorectal Cancer is Linked to Diagnostic Context, Not MMR Gene Defect** Noah Cornelis Helderman, Netherlands **Peripheral Immunophenotyping Reveals Cancer-Related Alterations in Lynch Syndrome** István Kelemen, Hungary **Remodeling of the Intestinal Immune Infiltrate and Integrin Signatures of Tissue- Resident CD8⁺ T Cells in Lynch Syndrome** Jacob Nattermann, Germany **Pre-empting Vaccine Barriers in Lynch Syndrome: Profiling Immune Evasion Across Precancerous Progression** Nicole Cianci, United Kingdom		
10:10 - 10:40	*Coffee/Tea Break*	*Laguna Ballroom* **Industry Sponsored Talk:** **Diving Deeper Into the Genome with Illumina Constellation Mapped Reads** Simeen Malek, Singapore Alvin Ng, Singapore illumina	
10:40 - 12:30	**Session 4: Genetics and Molecular Insights in Hereditary Gastrointestinal Tumours 2** Chairs: Daniel Buchanan, Australia Benjamin Zare, United Kingdom [Y-InSiGHT]		
10:40 - 11:00	**Adenoma-Carcinoma Model: Time to Move On** Aysel Ahadova, Germany		
11:00 - 11:20	**Germline Mosaicism in the Clinic: When to Suspect, How to Manage** Maartje Nielsen, Netherlands		
11:20 - 12:30	**Abstract Presentations 4** Chairs: Ingrid Winship, Australia | Hidewaki Nakagawa, Japan **Evidence For Mlh3 As A Cause For Colorectal Polyposis – A Multinational Study** Olkinuora Alisa, Switzerland **Molecular Landscapes Of Colorectal Polyps And Cancers From Serrated Polyposis Syndrome Patients With Germline Rnf43 Variants** Jihoon E. Joo, Australia **Germline Pathogenic Variants In Homologous Recombination Repair Pathway Genes And The Presence Of The Homologous Recombination Deficiency Mutational Signature In Early-onset Colorectal Cancer** Daniel Buchanan, Australia **Towards Prevention Of Replication Repair Deficient Childhood Cancers Using Neoantigen Mrna-lnp Vaccine** Sunam Mander, Canada **Clinical, Molecular, And Functional Insights Into Pole And Pold1 Proofreading Deficiency** Laura Valle, Spain **Mismatch Repair Deficiency In Histologically Normal Appearing Normal Urothelium In Lynch Syndrome Carriers** Matthias Kloor, Germany **Investigating Somatic And Rare Germline Mechanisms In Patients With Unexplained Mismatch Repair Deficiency** Giovana Tardin Torrezan, Brazil		
12:30 - 13:50	*Lunch Break*	**Poster Judging Session A**	

Programme

5 March, Thursday | Main Congress Day 2

13:50 - 15:40	**Session 5: Polyposis and Desmoid Management** Chairs: Finlay Macrae, Australia Claudia Wu, Hong Kong SAR		
13:50 - 14:10	**Current Best Practices and Emerging Therapies in Desmoid Management** Susan Clark, United Kingdom		
14:10 - 14:30	**Role of Small Bowel Intestinal Transplantation in Surgical Management of FAP** David Liska, United States		
14:30 - 15:40	**Abstract Presentations 5** Chairs: Marc Greenblatt, United States | Diantha Terlouw, Netherlands [Y-InSiGHT] **Defining the Risk of Desmoid Disease Following Surgery in Familial Adenomatous Polyposis (FAP) Patients with a Low Risk Genotype** Andrew Latchford, United Kingdom **Defining The Picture of Desmoid Disease in Children and Young Adults with Familial Adenomatous Polyposis** Benjamin Zare, United Kingdom **Novel Endoscopic Classification for Duodenal Polyposis in Individuals with Familial Adenomatous Polyposis: The DRACO multi-center study** Marco Vitellaro, Italy **Clinical Syndromes Linked To Biallelic Germline Variants In Mcm8 And Mcm9** Noah Cornelis Helderman, Netherlands **Outcomes Following Endoscopic Versus Transduodenal Resection In Fap Patients With Duodenal Adenomas: A Meta-analysis** Divya L Deverakonda, United States **Comparison Of Desmoid Disease Risk After Prophylactic Minimally Invasive Versus Open Restorative Proctocolectomy In Patients With Fap** Susan Clark, United Kingdom **The Role Of Genotoxic Gut Bacteria In Serrated Polyposis Syndrome And Unexplained Adenomatous Polyposis** Yen Lin Chu, Australia		
15:40 - 16:10	*Coffee/Tea Break*	*Albatross & Birdie* **Get to Know Journal of Gastropenterology and Hepatology (JGH) Session** Rakesh Aggarwal, Chair, Journal of Gastroenterology and Hepatology Foundation	*Laguna Ballroom* **Industry Sponsored Talk: AI in Precision Medicine on AWS** Charlie Lee, Singapore Mai Chan Lau, Singapore aws
16:10 - 17:40	**Session 6: Polyposis Management and Pathology** Chairs: Ian Frayling, United Kingdom M Logaswari, Singapore		
16:10 - 16:30	**Role of Local Excision and Organ-Preserving Strategies in Hereditary Gastrointestinal Cancer** Matthew Kalady, United States *(Society of Colorectal Surgeons Singapore nominated speaker)*		
16:30 - 16:50	**Use of AI in Colorectal Cancer Pathology** Leow Wei Qiang, Singapore *(International Academy of Pathology (Singapore Division) nominated speaker)*		
16:50 - 17:40	**Abstract Presentations 6** Chairs: Andrew Latchford, United Kingdom | Ernest Eu, Singapore **Using Oxford Nanopore Technologies Long-read Sequencing To Resolve Unexplained Hereditary Colorectal Cancer And Polyposis Syndrome Patients** Jihoon E. Joo, Australia **Small Bowel Surveillance Investigations, Interventions And Outcomes In A Large Uk Peutz-jeghers Syndrome Cohort** Roshani Patel, United Kingdom **Duodenal Involvement In Mutyh-associated Polyposis: Findings From An International Prospective Study And Implications For Endoscopic Surveillance** Imogen Bennett, United Kingdom **Risk Of Colorectal Cancer In Li Fraumeni Syndrome** Stephen B. Gruber, United States **Molecular And Clinicopathological Profiling Of Desmoid Tumours In Familial Adenomatous Polyposis Through Rna Sequencing Analysis** Benjamin Zare, United Kingdom		
17:40 - 18:40	**Poster Judging Session B**		
18:40 - 18:55	**Day 2 Adjourn**		
19:30 - 22:00	*Violet Oon* **Council Dinner** *(By invite only)*	*Offsite* **Night Safari Tour** *(Ticketed)*	

Programme

6 March, Friday | Main Congress Day 3

07:30 - 08:20	*Albatross & Birdie* **InSiGHT Asia Chapter / ICaN Asia Meeting** Chairs: Joanne Ngeow, Singapore Finlay Macrae, Australia		
Time	*Laguna Ballroom*		
08:30 - 10:30	**Session 7: Hereditary Gastric Cancer Surveillance and Management** *Chairs: Bryson Katona, United States* *Tan Yu Bin, Singapore*		
08:30 - 08:50	**Best Practices in Gastric Cancer Care for High Risk Patients** Jean Christophe Saurin, France *(Gastroenterological Society of Singapore nominated speaker)*		
08:50 - 09:10	**Hereditary Diffuse Gastric Cancer (HDGC): Pathological Insights and Clinical Implications** Chella van der Post, Netherlands		
09:10 - 09:50	**Abstract Presentations 7** Chairs: Intan Schrader, Canada | Laden Goshayeshi, Iran **Penetrance Of Cdh1 Pathogenic Variants: A Multicenter Analysis From The Gastric Consortium** Ophir Gilad, United States **Clinical Outcomes and Management of Gastric White Mucosal Patches in Patients with Familial Adenomatous Polyposis** Carol Burke, United States **Outcomes Of Gastric Surveillance In Juvenile Polyposis Syndrome** Victoria Cuthill, United Kingdom **Longitudinal Analysis Of Fundic Gland Cysts As Predictors Of Gastric Neoplasia In Familial Adenomatous Polyposis** Robert Hüneburg, Germany		
09:50 - 10:30	**Panel Discussion** Moderator: Andrew Latchford, United Kingdom Panellists: Evelien Dekker, Netherlands Carol Burke, United States		
10:30 - 11:00	*Coffee/Tea Break*	*Laguna Ballroom* **Meet-the-Expert** **Industry Sponsored Talk: Evaluating PacBio Long Read Sequencing for Resolving Cancer Predisposition Variants in Singapore** Alvin Ng Wei Tian, Singapore PacBio	
11:00 - 12:40	**Session 8: Advances in Pancreatic Cancer Research** Chairs: Laura Valle, Spain Chenlei Wen, China		
11:00 - 11:20	**Update from PRECEDE Study** Diane Simeone, United States *(Hepato Pancreato Biliary Association nominated speaker)*		
11:20 - 11:40	**Early Onset Pancreastic Cancer in China: Contribution of Genetics** Shen Baiyong, China		
11:40 - 12:40	**Abstract Presentations 8** Chairs: Sharon Plon, United States | Frances Victoria F. Que, Philippines **Prevalence Ff Germline Pathogenic Variants Among Pancreatic Cancer Patients in Singapore** Nur Diana Binte Ishak, Singapore **Parent-of-Origin-Aware genomic analysis Enhances the Genetic Risk Assessment in Pancreatic Ductal Adenocarcinoma** Kasmintan A Schrader, Canada **Yield of Germline Genetic Testing among Families with Pancreatic Cancer Clustering** Asaf Maoz, United States **Clinical Characteristics and Outcomes of Pancreatic Cancer Patients with Germline HRD Mutations: A Retrospective Cohort Study** Zewen Zhang, Singapore **Lynch Syndrome - Pancreatic Cancer Risk and Survival: A Nationwide Dutch Cohort Study** Monique van Leerdam, Netherlands **Gastrointestinal Cancer Risks in Israeli BRCA1/BRCA2 Mutation Carriers** Sari Lieberman, Israel		
12:40 - 14:00	*Lunch Break*	*Speakers' Ready Room* **Council Meeting** *(InSiGHT Council Members Only)*	*Albatross & Birdie* **CMMRD Workshop** Chairs: Uri Tabori, Canada Anirban Das, Canada Lucie Stengs, Canada
14:00 - 15:30	**Session 9: Advances in Lynch Syndrome Research 1** Chairs: Raj Ramesar, South Africa Mev Domínguez Valentin, Norway		

Disclaimer: The programme is accurate as of the time of publication. It is subject to change at the discretion of the Organising Committee without prior notice.

Programme

6 March, Friday | Main Congress Day 3

14:00 - 14:20	**Lynch Syndrome Screening, And Diagnosis and Management: The Chinese Experience** Ding Peirong, China		
14:20 - 15:30	**Abstract Presentations 9** Chairs: Raj Ramesar, South Africa | Mev Domínguez Valentin, Norway **A Systematic Review And Meta-analysis On Colorectal Neoplasia Detection In Lynch Syndrome** Stephanie Poo, United Kingdom **Incidence And Predictors of Advanced Neoplasia In Patients with Lynch Syndrome on Surveillance Colonoscopy Performed at or after Age 65 years** Carol A. Burke, United States **Adenoma Incidence Trends by Genotype in Lynch Syndrome: A Retrospective Cohort Study of 318 MD Anderson Cancer Center Patients** Luigi Ricciardiello, United States **Impact Of Surveillance Colonoscopy On Colorectal Cancer Incidence And Mortality In Lynch Syndrome: An Observational Cohort Study** Kevin Monahan, United Kingdom **Potential Impact of AI-assisted Colonoscopy on Non-AI Performance in Lynch Syndrome Surveillance: Evidence of a Skill Effect** Tim Marwitz, Germany **Deep Learning Model Distinguishes Lynch Syndrome from Sporadic MSI-H using Adenoma Histology** Srividhya Sainath, Germany		
15:30 - 16:00	*Coffee/Tea Break*	*Albatross & Birdie* **Get to Know Familial Cancer Session** Gabriel Capellá, Editors-in-Chief, Familial Cancer Hans Vasen, Editors-in-Chief, Familial Cancer	*Laguna Ballroom* Oxford Nanopore Technologies **Industry Sponsored Talk: Reveal More Cancer Biology with Ultra-rich Oxford Nanopore Sequencing Data** Manop Pithukpakorn, Thailand Lei Tong, Singapore
16:00 - 17:40	**Session 10: Advances in Lynch Syndrome Research 2** Chairs: Maria Katapodi, Switzerland Rakefet Shtoyerman, Israel		
16:00 - 16:20	**Implementing Population Genomics for Hereditary GI Cancer Prevention: Lessons from PROTECT** Ranjit Manchanda, United Kingdom		
16:20 - 17:40	**Abstract Presentations 10** Chairs: Maria Katapodi, Switzerland | Rakefet Shtoyerman, Israel **Cancer Risks In First-degree Relatives Of Individuals With Biallelic Somatic Dna Mismatch Repair Mutations** Romy Walker, Australia **A Multiplex Assay Of Variant Effect (Mave) Of Msh6 Enables Accurate, Prospective Lynch Syndrome Clinical Variant Interpretation** Anthony Scott, United States **Reassessing MSH6 variants in ClinVar using MMR-specific ACMG/AMP guidelines and recent literature** Hashini Kristhorubaduge, Australia **Immunogenic Frameshift Mutations In Patients With Lynch Syndrome And Immune Suppression Programs Supporting Colorectal Cancer Development** Aimee L. Lucas, United States **Prospective Evaluation of a Blood-Based Digital PCR MSI Assay for Early Colorectal Cancer Detection in Lynch Syndrome Carriers: the BioLynch Study** Mattia Boeri, Italy **Blood-based T Cell Clonal Expansion As A Biomarker Of Mismatch Repair-deficient Tumours In Lynch Syndrome** Penelope Edwards, United Kingdom **Mapping the T Cell Receptor Repertoire in Lynch Syndrome-associated Colorectal Cancer** Penelope Edwards, United Kingdom **Neoantigen-loaded dendritic cell vaccine for cancer prevention in Lynch Syndrome: Early results from a phase Ib clinical trial** Joaquín Castillo-Iturra, Spain		
17:40 - 18:20	**InSiGHT General Meeting**		
18:20 - 18:35	**Day 3 Adjourn**		
19:00 Onwards	*Hopscotch (Gardens By The Bay)* **Congress Dinner**		

Disclaimer: The programme is accurate as of the time of publication. It is subject to change at the discretion of the Organising Committee without prior notice.

Programme

7 March, Saturday | Main Congress Day 4

08:00 - 08:50	*Laguna Ballroom* **EOCRC Hour** Chairs: Daniel Buchanan, Australia Alvin Ng, Singapore	*Albatross & Birdie* **Collab Lab @ InSiGHT** Chair: Joanne Ngeow, Singapore
Time	*Laguna Ballroom*	
09:00 - 09:15	**Address by Guest of Honour** Koh Poh Koon, Senior Minister of State for Health and Manpower, Singapore	
09:15 - 10:45	**Session 11: Best Oral Communications** Chairs: Francesc Balaguer, Spain Romy Walker, Australia	
09:15 - 10:45	**Best Oral Communications** Chairs: Francesc Balaguer, Spain | Romy Walker, Australia **The Newcastle MSI-Plus Assay for Low Cost and Scalable Lynch Syndrome Screening of Cancer Patients and Urine-based Early Detection of Lynch Syndrome Urothelial Cancer** Richard Gallon, United Kingdom **TA-Repeat Expansions Drive WRN Dependency and Guide Inhibitor Therapy in Sporadic and Lynch-Associated MSI Cancers** Gabriele Picco, United Kingdom **Comparison of Postoperative Morbidity Following Total Colectomy with Ileorectal Anastomosis vs Proctocolectomy with Ileal Pouch-anal Anastomosis in Familial Adenomatous Polyposis** Jared R Hendren, United States **Cap-assisted vs. Side-viewing Duodenoscopy for Papilla Vi sualization in Familial Adenomatous Polyposis: a Randomized Blinded Cross-over Trial (CAPFAP)** Robert Hüneburg, Germany **Pancreatic Cancer Surveillance Not Recommended for Familial Adenomatous Polyposis: A Fine And Gray Risk Analysis** Monique van Leerdam, Netherlands **Systemic Markers for Predicting and Monitoring Response to Immune Checkpoint Blockade Therapy in Patients with Advanced Microsatellite-unstable Gastrointestinal Cancers: A Pilot Study** Aysel Ahadova, Germany	
10:45 - 11:15	*Coffee/Tea Break*	
11:15 - 12:35	**Session 12: Frontiers in Lynch Syndrome Research** Chairs: Kevin Monahan, United Kingdom Rebecca Caeser, Singapore	
11:15 - 11:35	**Lynch Syndrome in Singapore: Insights Into The Local Landscape** Joanne Ngeow, Singapore	
11:35 - 11:55	**Cancer Vaccines in Lynch Syndrome - Progress and Promise** David Church, United Kingdom *(Singapore Society of Oncology nominated speaker)*	
11:55 - 12:15	**Cancer Prevention with Aspirin: CaPP3 and Beyond** Sir John Burn, United Kingdom	
12:15 - 12:35	**From Evidence to Practice: Updates on Lynch Sydrome Guidelines** Giulia Martina Cavestro, Italy	
12:35 - 12:55	**Concluding Remarks**	
	Lunch will not be provided. We encourage delegates to make their own dining arrangements.	
13:00 - 16:00	*Albatross & Birdie* **Living with Lynch Patient Conference** *(By Invite Only)*	

Disclaimer: The programme is accurate as of the time of publication. It is subject to change at the discretion of the Organising Committee without prior notice.

Oral Presentations

Time	Submission ID	Full Name	Abstract Topic	Abstract Title
Best Oral Communication | 7 March 2026				
09:00 - 09:15	OP-0058	Richard Gallon	Lynch Syndrome	The Newcastle MSI-Plus Assay for low cost and scalable Lynch syndrome screening of cancer patients and urine-based early detection of Lynch syndrome urothelial cancer
09:15 - 09:30	OP-0038	Gabriele Picco	Lynch Syndrome	TA-Repeat Expansions Drive WRN Dependency and Guide Inhibitor Therapy in Sporadic and Lynch-Associated MSI Cancers
09:30 - 09:45	EI-0097	Jared R Hendren	Familial Adenomatous Polyposis	Comparison of postoperative morbidity following total colectomy with ileorectal anastomosis vs proctocolectomy with ileal pouch-anal anastomosis in familial adenomatous polyposis
09:45 - 10:00	EI-0118	Robert Hüneburg	Familial Adenomatous Polyposis	Cap-assisted vs. side-viewing duodenoscopy for papilla visualization in familial adenomatous polyposis: a randomized blinded cross-over trial (CAPFAP)
10:00 - 10:15	EI-0010	Monique van Leerdam	Familial Adenomatous Polyposis	Pancreatic Cancer Surveillance Not Recommended For Familial Adenomatous Polyposis: A Fine And Gray Risk Analysis
10:15 - 10:30	OP-0028	Aysel Ahadova	Lynch Syndrome	Systemic markers for predicting and monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite-unstable gastrointestinal cancers: a pilot study
Abstract Presentation 1 | 4 March 2026				
15:00 - 15:10	OP-0064	Luis G Carvajal Carmona	Artificial Intelligence in Risk Assessment	Improving Colorectal Cancer Risk Prediction in Latinos Using Polygenic Scores and Machine Learning
15:10 - 15:20	OP-0065	Raj Ramesar	Studies in Asia and Underrepresented Populations	The Familial Cancer Experience in South Africa: A Model for Implementing Genomic Medicine in Developing Countries
15:20 - 15:30	EI-0011	Heather Hampel	Lynch Syndrome	Lynch Syndrome Re-Defined Through a Universal Germline Genetic Testing Program
15:30 - 15:40	OP-0041	Tan Wan Ling Andrea	Artificial Intelligence in Risk Assessment	Improving Hereditary GI Cancer Referral Rates using Electronic Health Records
Abstract Presentation 2 | 4 March 2026				
16:50 - 17:00	PP-0030	Sara Tasnim	Lynch Syndrome	Cost-effectiveness of Genetic Testing to Diagnose Lynch Syndrome in Singapore
17:00 - 17:10	OP-0013	Agnes Wong	Health Policy and Equity	Decision Regret and Willingness to Pay for Cancer Genetic Testing: A Longitudinal Contingent Valuation Study
17:10 - 17:20	EI-0137	Carla Oliveira	Hereditary Gastric Cancer Syndromes	Clinical Outcomes and Healthcare Costs in Hereditary Diffuse Gastric Cancer: A European Multicenter Study
17:20 - 17:30	EI-0028	Alicia Latham	Lynch Syndrome	Feasibility of Pap-derived cfDNA for early-detection of sporadic and Lynch-associated endometrial and ovarian cancers
Abstract Presentation 3 | 5 March 2026				
09:10 - 09:20	OP-0027	Aysel Ahadova	Lynch Syndrome	Somatic CTNNB1 mutations as a positive predictor of Lynch syndrome
09:20 - 09:30	EI-0012	Taina T Nieminen	Novel Genes in Hereditary GI Tumours	Inflammasome-related gene variant predisposing to familial colorectal carcinoma
09:30 - 09:40	OP-0011	Noah Cornelis Helderman	Lynch Syndrome	Immune infiltration in Lynch syndrome colorectal cancer is linked to diagnostic context, not MMR gene defect
09:40 - 09:50	OP-0014	István Kelemen	Lynch Syndrome	Peripheral immunophenotyping reveals cancer-related alterations in Lynch syndrome
09:50 - 10:00	EI-0108	Jacob Nattermann	Lynch Syndrome	Remodeling of the Intestinal Immune Infiltrate and Integrin Signatures of Tissue- Resident CD8⁺ T Cells in Lynch Syndrome
10:00 - 10:10	EI-0142	Nicole Cianci	Lynch Syndrome	Pre-empting Vaccine Barriers in Lynch Syndrome: Profiling Immune Evasion Across Precancerous Progression
Abstract Presentation 4 | 5 March 2026				
11:20 - 11:30	EI-0039	Olkinuora Alisa	Novel Genes in Hereditary GI Tumours	Evidence for MLH3 as a cause for colorectal polyposis – a multinational study
11:30 - 11:40	OP-0047	Jihoon E. Joo	Other Polyposis Syndromes	Molecular landscapes of colorectal polyps and cancers from serrated polyposis syndrome patients with germline RNF43 variants
11:40 - 11:50	OP-0043	Daniel Buchanan	Novel Genes in Hereditary GI Tumours	Germline pathogenic variants in homologous recombination repair pathway genes and the presence of the homologous recombination deficiency mutational signature in early-onset colorectal cancer
11:50 - 12:00	EI-0087	Sunam Mander	Pediatric Hereditary GI Tumour Syndromes	Towards prevention of replication repair deficient childhood cancers using neoantigen mRNA-LNP Vaccine
12:00 - 12:10	EI-0072	Laura Valle	Other Polyposis Syndromes	Clinical, molecular, and functional insights into POLE and POLD1 proofreading deficiency
12:10 - 12:20	OP-0062	Matthias Kloor	Lynch Syndrome	Mismatch repair deficiency in histologically normal appearing normal urothelium in Lynch syndrome carriers
12:20 - 12:30	OP-0052	Giovana Tardin Torrezan	Lynch Syndrome	Investigating somatic and rare germline mechanisms in patients with unexplained mismatch repair deficiency

Oral Presentations

Time	Submission ID	Full Name	Abstract Topic	Abstract Title
Abstract Presentation 5 | 5 March 2026				
14:30 - 14:40	EI-0067	Andrew Latchford	Familial Adenomatous Polyposis	Defining the risk of desmoid disease following surgery in familial adenomatous polyposis (FAP) patients with a low risk genotype
14:40 - 14:50	EI-0007	Benjamin Zare	Familial Adenomatous Polyposis	Defining the picture of desmoid disease in children and young adults with familial adenomatous polyposis
14:50 - 15:00	EI-0114	Marco Vitellaro	Familial Adenomatous Polyposis	Novel Endoscopic Classification for Duodenal Polyposis in Individuals with Familial Adenomatous Polyposis: the DRACO multi-center study.
15:00 - 15:10	OP-0010	Noah Cornelis Helderman	Other Polyposis Syndromes	Clinical syndromes linked to biallelic germline variants in MCM8 and MCM9
15:10 - 15:20	EI-0089	Divya L Deverakonda, MD	Familial Adenomatous Polyposis	Outcomes following endoscopic versus transduodenal resection in FAP patients with duodenal adenomas: a meta-analysis
15:20 - 15:30	EI-0049	Susan Clark	Familial Adenomatous Polyposis	Comparison of desmoid disease risk after prophylactic minimally invasive versus open restorative proctocolectomy in patients with FAP
15:30 - 15:40	OP-0040	Yen Lin Chu	Microbiome and Environmental Modifiers	The role of genotoxic gut bacteria in serrated polyposis syndrome and unexplained adenomatous polyposis
Abstract Presentation 6 | 5 March 2026				
16:50 - 17:00	OP-0045	Jihoon E. Joo	Familial Adenomatous Polyposis	Using Oxford Nanopore Technologies long-read sequencing to resolve unexplained hereditary colorectal cancer and polyposis syndrome patients
17:00 - 17:10	EI-0127	Roshani Patel	Other Polyposis Syndromes	Small bowel surveillance investigations, interventions and outcomes in a large UK Peutz-Jeghers syndrome cohort
17:10 - 17:20	EI-0037	Imogen Bennett	Other Polyposis Syndromes	Duodenal involvement in MUTYH-associated polyposis: findings from an international prospective study and implications for endoscopic surveillance
17:20 - 17:30	OP-0023	Stephen B. Gruber	Novel Genes in Hereditary GI Tumours	Risk of Colorectal Cancer in Li Fraumeni Syndrome
17:30 - 17:40	EI-0052	Benjamin Zare	Familial Adenomatous Polyposis	Molecular and clinicopathological profiling of desmoid tumours in familial adenomatous polyposis through RNA sequencing analysis.
Abstract Presentation 7 | 6 March 2026				
09:10 - 09:20	EI-0088	Carol Burke	Familial Adenomatous Polyposis	Clinical Outcomes and Management of Gastric White Mucosal Patches in Patients with Familial Adenomatous Polyposis
09:20 - 09:30	EI-0020	Ophir Gilad	Hereditary Gastric Cancer Syndromes	Penetrance Of Cdh1 Pathogenic Variants: A Multicenter Analysis From The Gastric Consortium
09:30 - 09:40	EI-0125	Victoria Cuthill	Other Polyposis Syndromes	Outcomes of gastric surveillance in juvenile polyposis syndrome
09:40 - 09:50	EI-0130	Robert Hüneburg	Familial Adenomatous Polyposis	Longitudinal analysis of fundic gland cysts as predictors of gastric neoplasia in familial adenomatous polyposis
Abstract Presentation 8 | 6 March 2026				
11:40 - 11:50	EI-0063	Nur Diana Binte Ishak	Hereditary Pancreatic Cancer Syndromes	Prevalence Of Germline Pathogenic Variants Among Pancreatic Cancer Patients in Singapore
11:50 - 12:00	EI-0083	Kasmintan A Schrader	Hereditary Pancreatic Cancer Syndromes	Parent-of-Origin-Aware genomic analysis Enhances the Genetic Risk Assessment in Pancreatic Ductal Adenocarcinoma
12:00 - 12:10	EI-0003	Asaf Maoz	Hereditary Pancreatic Cancer Syndromes	Yield of Germline Genetic Testing among Families with Pancreatic Cancer Clustering
12:10 - 12:20	EI-0054	Zewen Zhang	Hereditary Pancreatic Cancer Syndromes	Clinical Characteristics and Outcomes of Pancreatic Cancer Patients with Germline HRD Mutations: A Retrospective Cohort Study
12:20 - 12:30	EI-0009	Monique van Leerdam	Lynch Syndrome	Lynch Syndrome - Pancreatic Cancer Risk And Survival: A Nationwide Dutch Cohort Study
12:30 - 12:40	EI-0124	Sari Lieberman	Hereditary Pancreatic Cancer Syndromes	Gastrointestinal cancer risks in Israeli BRCA1/BRCA2 mutation carriers

Oral Presentations

Time	Submission ID	Full Name	Abstract Topic	Abstract Title
Abstract Presentation 9 | 6 March 2026				
14:20 - 14:30	EI-0022	Stephanie Poo	Lynch Syndrome	A systematic review and meta-analysis on colorectal neoplasia detection in Lynch syndrome
14:30 - 14:40	OP-0026	Carol A. Burke	Lynch Syndrome	Incidence And Predictors of Advanced Neoplasia In Patients with Lynch Syndrome on Surveillance Colonoscopy Performed at or after Age 65 years
14:40 - 14:50	PP-0028	Luigi Ricciardiello	Lynch Syndrome	Adenoma Incidence Trends by Genotype in Lynch Syndrome: A Retrospective Cohort Study of 318 MD Anderson Cancer Center Patients
14:50 - 15:00	OP-0005	Kevin Monahan	Lynch Syndrome	Impact of surveillance colonoscopy on colorectal cancer incidence and mortality in Lynch syndrome: an observational cohort study
15:00 - 15:10	OP-0048	Hugo Montemont	Lynch Syndrome	Non-Neoplastic Precursor Lesions and Somatic Alterations in Lynch Syndrome–Associated Upper Gastrointestinal Cancers
15:10 - 15:20	EI-0140	Tim Marwitz	Artificial Intelligence in Risk Assessment	Potential impact of AI-assisted colonoscopy on non-AI performance in Lynch syndrome surveillance: evidence of a skill effect
15:20 - 15:30	EI-0133	Srividhya Sainath	Lynch Syndrome	Deep Learning Model Distinguishes Lynch Syndrome from Sporadic MSI-H using Adenoma Histology
Abstract Presentation 10 | 6 March 2026				
16:20 - 16:30	OP-0042	Romy Walker	Hereditary Gastric Cancer Syndromes	Cancer risks in first-degree relatives of individuals with biallelic somatic DNA mismatch repair mutations
16:30 - 16:40	EI-0013	Anthony Scott	Lynch Syndrome	A multiplex assay of variant effect (MAVE) of MSH6 enables accurate, prospective Lynch Syndrome clinical variant interpretation
16:40 - 16:50	PP-0018	Hashini Kristhorubaduge	Lynch Syndrome	Reassessing MSH6 variants in ClinVar using MMR-specific ACMG/AMP guidelines and recent literature
16:50 - 17:00	EI-0047	Aimee L. Lucas	Lynch Syndrome	Immunogenic frameshift mutations in patients with Lynch syndrome and immune suppression programs supporting colorectal cancer development
17:00 - 17:10	OP-0029	Mattia Boeri	Lynch Syndrome	Prospective Evaluation of a Blood-Based Digital PCR MSI Assay for Early Colorectal Cancer Detection in Lynch Syndrome Carriers: the BioLynch Study
17:10 - 17:20	EI-0110	Penelope Edwards	Lynch Syndrome	Blood-based T cell clonal expansion as a biomarker of mismatch repair-deficient tumours in Lynch syndrome
17:20 - 17:30	EI-0036	Penelope Edwards	Lynch Syndrome	Mapping the T Cell Receptor Repertoire in Lynch Syndrome-Associated Colorectal Cancer
17:30 - 17:40	EI-0147	Joaquín Castillo-Iturra	Lynch Syndrome	Neoantigen-loaded dendritic cell vaccine for cancer prevention in Lynch Syndrome: Early results from a phase Ib clinical trial

Poster Display Panels



Row	Grouping	Panel Number	Abstract Topic
Row 1	Group 1	Panel number 1 - 21	Lynch Syndrome
	Group 2	Panel number 22 - 43	Lynch Syndrome
Row 2	Group 3	Panel number 44 - 62	Lynch Syndrome
Row 3	Group 4	Panel number 63 - 85	Familial Adenomatous Polyposis
Row 4	Group 5	Panel number 86 - 104	Other Polyposis Syndromes
	Group 6	Panel number 105 - 112	Hereditary Gastric Cancer Syndromes
		Panel number 113 - 118	Hereditary Gastric Cancer Syndromes
		Panel number 119 - 123	Novel Genes in Hereditary GI Tumours
	Group 7	Panel number 124	Microbiome and Environmental Modifiers
		Panel number 125 - 126	Germline Mosaicism in Hereditary GI Tumours
		Panel number 127 - 133	Pediatric Hereditary GI Tumour Syndromes
Row 5	Group 8	Panel number 134 - 138	Health Policy and Equity
		Panel number 139 - 151	Studies in Asia and Underrepresented Populations
	Group 9	Panel number 152 - 153	Artificial Intelligence in Risk Assessment
		Panel number 154 - 157	Digital Health in Hereditary GI Cancer
		Panel number 158 - 162	Implementation Science in Hereditary Cancer
		Panel number 163 - 166	Non-Physician Providers in Cancer Management

The above serves as an overview of poster groupings only.

Kindly refer to the following for the Poster Display Panels. Panel numbers, authors' names, and abstract IDs are displayed on the information board at each row.

Poster Judging Session Details

5 March 2026
Session A: 12:30 - 13:50
Session B: 17:40 - 18:40

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 1 | GROUP 1					
1	EI-0001	Robert Rudolf Kikkert	Netherlands	Lynch Syndrome	Surveillance for urothelial carcinoma in Lynch syndrome
2	EI-0002	Hidetaka Kawamura	Japan	Lynch Syndrome	Complete Response to Immune Checkpoint Inhibitor and Chemoradiotherapy in a Lynch Syndrome Parent-Child Pair With MSI-High Rectal Cancer
3	EI-0005	Anja Wagner	Netherlands	Lynch Syndrome	Screening for endometrial precursor lesions in female Lynch syndrome carriers
4	EI-0006	Akinari Takao	Japan	Lynch Syndrome	Characteristics of colorectal lesions and the extracolonic tumor risk in Lynch syndrome: A Japan-wide multicentric cohort study
5	EI-0015	Brandie Heald Leach	United States	Lynch Syndrome	Uptake of Clinical Interventions Following Germline Genetic Testing for Hereditary Endometrial Cancer: A Systematic Review
6	EI-0021	Atsushi Yamada	Japan	Lynch Syndrome	Occurrence of colorectal advanced neoplasia and adenoma during postoperative surveillance in patients with early-onset colorectal cancer
7	EI-0023	Xiao Dan Chen	China	Lynch Syndrome	Using system dynamics modeling and group model building to identify barriers and facilitators of genetic testing for hereditary cancer in Singapore
8	EI-0025	Erdogan Pekcan Erkan	Finland	Lynch Syndrome	Single-cell transcriptomic profiling reveals tumor microenvironmental divergence between Lynch syndrome-associated and sporadic colorectal cancers
9	EI-0027	Susan Parry	New Zealand	Lynch Syndrome	Integrating Molecular Genetics Expertise into Multidisciplinary Review of Lynch-Like patients improves clinical decision making
10	EI-0038	Simeen Malik	Singapore	Lynch Syndrome	Haplotype-resolved variant detection in medically relevant and paralogous genes using multi-region joint detection with Illumina constellation mapped reads
11	EI-0043	Uri Tabori	Canada	Lynch Syndrome	Immunoediting affects clonal evolution, mutational burden, and response to immunotherapy of replication repair-deficient cancers
12	EI-0044	Zoya Aamir	Canada	Lynch Syndrome	Replication repair deficient mouse models provide insights into gliomagenesis and response to immunotherapy
13	EI-0050	Frances Victoria Que	Philippines	Lynch Syndrome	Underutilization of Lynch Syndrome Testing in Filipino Colorectal Cancer Patients: Bridging the Diagnostic Gap
14	EI-0056	Jeff Crimson San Jose Ordoñe	Philippines	Lynch Syndrome	A Tale of Three Tumors: Unmasking a Hereditary Cancer Syndrome - Case of Metastatic Jejunal Adenocarcinoma in a 62-Year-Old Female with Lynch Syndrome
15	EI-0060	Akira Sakamoto	Japan	Lynch Syndrome	Incidence and Treatment Selection of Metachronous Colorectal Cancer in Patients with Lynch Syndrome
16	EI-0065	Clorinda Brignola	Italy	Lynch Syndrome	Decoding Uncertainty: Clinical Reclassification of MLH1 VUS in Lynch Syndrome.
17	EI-0066	Yong Quan Lee	Australia	Lynch Syndrome	Genetic testing outcomes in 242 bowel cancer patients from a statewide public genetic service in Queensland, Australia
18	EI-0073	Giada Sassi	Italy	Lynch Syndrome	Dietary habits and Body Composition in Lynch Syndrome Patients: Preliminary Results from BioLynch Prospective Study
19	EI-0075	Anja Wagner	Netherlands	Lynch Syndrome	Diagnostic functional analysis can make the difference in clinical care for Lynch and CMMRDS patients
20	EI-0080	Anja Wagner	Netherlands	Lynch Syndrome	Diagnostic and clinical challenges in an African family with Lynch syndrome
21	EI-0091	Sonia Kupfer	United States	Lynch Syndrome	Lynch syndrome INtegrative Epidemiology and GEnetics (LINEAGE) Consortium

Laguna Ballroom 3 Poster Panels

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Poster Panel 1 - 12: Session A
Poster Panel 13 - 20: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
			ROW 1 | GROUP 2		
22	EI-0093	Bryson Katona	United States	Lynch Syndrome	β-Hydroxybutyrate Supplementation As A Potential Chemoprevention Strategy In Lynch Syndrome
23	EI-0098	Maurizio Genuardi	Italy	Lynch Syndrome	Mainstreaming the diagnosis of Lynch Syndrome (LS) in colorectal cancer (CRC) patients: the ItaLynch st
24	EI-0102	Alvin Wei Tian Ng	Singapore	Lynch Syndrome	Deciphering the risk factors of colorectal cancer using Oxford Nanopore long read sequencing
25	EI-0103	Jared R Hendren	United States	Lynch Syndrome	Hereditary Cancer Registry Enrollment Improves Surveillance Uptake in Lynch Syndrome
26	EI-0104	Reagan Barnett	United States	Lynch Syndrome	Pan-cancer assessment of MLH1 promoter methylation utilizing a liquid biopsy platform
27	EI-0111	Katrin van Beekum	Germany	Lynch Syndrome	Upper Gastrointestinal Surveillance in Lynch Syndrome
28	EI-0112	Katrin van Beekum	Germany	Lynch Syndrome	Ileal Neoplasia in Lynch Syndrome Patients
29	EI-0113	Davide Ferrari	Italy	Lynch Syndrome	Hereditary Tumor Registry: What we can learn for Precision Prevention in Lynch Syndrome.
30	EI-0115	Jessica Vadaketh	United States	Lynch Syndrome	Repeat Gastric Body and Antrum Biopsies in Lynch Syndrome Yield Newly Identified Gastric Intestinal Metaplasia
31	EI-0116	Irene A. Caspers	Netherlands	Lynch Syndrome	Upper-gastrointestinal cancer in Lynch syndrome individuals in a country with and a country without surveillance
32	EI-0119	Antonia Schuler	Germany	Lynch Syndrome	Early-Onset and Multifocal Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights from a Large Cohort
33	EI-0120	Alethea Tang	United Kingdom	Lynch Syndrome	Serum Raman spectroscopy and correlation with metabolomic profiles in colorectal surveillance for Lynch syndrome
34	EI-0121	Antonia Schuler	Germany	Lynch Syndrome	Clinical characteristics of prostate cancer in men with Lynch syndrome: Data from the German Consortium for Familial Intestinal Cancer
35	EI-0122	BENEDITO MAURO ROSSI	Brazil	Lynch Syndrome	Cancer Spectrum and Gene-Specific Patterns in Lynch Syndrome: Insights from 47 Families in a Brazilian Institutional Cohort
36	EI-0123	Antonia Schuler	Germany	Lynch Syndrome	Renal cell carcinoma in Lynch syndrome: Clinical characteristics from the German Consortium for Familial Intestinal Cancer
37	EI-0126	Kimia Mohammadsaeedi	Australia	Lynch Syndrome	Systematic review of MLH1 constitutional methylation in Lynch Syndrome
38	EI-0131	Vanessa García López-Mingo	Netherlands	Lynch Syndrome	Modeling adenoma development and progression in Lynch syndrome in order to personalize surveillance
39	EI-0134	Katarina Dian Andini	Netherlands	Lynch Syndrome	Spatially-directed gene expression profiling of PMS2 Lynch syndrome-associated adenomas
40	EI-0143	Ann-Sofie Backman	Sweden	Lynch Syndrome	Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP. Report on the ongoing multicenter, multinational, randomized, two-arm, double-blind, phase II clinical study with Mesalamine versus placebo in carriers with Lynch Syndrome
41	EI-0144	Megan Hitchins	United States	Lynch Syndrome	Observational studies combined with long-read nanopore sequencing in families with constitutional MLH1 epimutation reveal distinct mechanisms and patterns of inheritance
42	EI-0145	Stephanie X. Poo	United Kingdom	Lynch Syndrome	Quality and diagnostic outcomes of UK Lynch syndrome colonoscopy surveillance from the National Endoscopy Database
43	OP-0004	Amalia Nicole Nanciu	Germany	Lynch Syndrome	Overview of Lynch Syndrome (LS) guidelines across Europe: Similarities, differences, and future directions

ROW 1

Laguna Ballroom 3 Poster Panels

Poster Panel 22 - 32: Session A
Poster Panel 33 - 40: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
			ROW 2 | GROUP 3		
44	OP-0021	Robert Hüneburg	Germany	Lynch Syndrome	CADLY2: An International Randomized Trial of AI-Assisted Colonoscopy in Lynch Syndrome (Interim Status)
45	OP-0024	Swati G Patel	United States	Lynch Syndrome	Rate and Root Cause Analysis of Post-Colonoscopy Colorectal Cancer in Lynch Syndrome: The Potential of the LINEAGE Consortium
46	OP-0033	Anna Magdalena Scheßl	Germany	Lynch Syndrome	Epigenetic Modulation for Treatment and Prevention of Mismatch Repair-Deficient Tumors
47	OP-0036	Ladan goshayeshi	Iran	Lynch Syndrome	Comprehensive Analysis of Germline Variants in Iranian Patients with Hereditary Colorectal Cancer
48	OP-0037	Marjorie de la Fuente	Chile	Lynch Syndrome	Lynch Syndrome in Latin America: Genetic and Clinical Profiles from a Multicenter Cohort
49	OP-0044	Aung Ko Win	Australia	Lynch Syndrome	Variation in the Risk of Endometrial Cancer for Lynch Syndrome: A Retrospective Family Cohort Study
50	OP-0049	Elizabeth Half	Israel	Lynch Syndrome	High Yield of Actionable Gastroduodenal Findings Among Lynch Syndrome Patients Undergoing Esophagogastroduodenoscopy (EGD) surveillance
51	OP-0050	Mev Dominguez Valentin	Norway	Lynch Syndrome	Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH)
52	OP-0057	Marta Pineda	Spain	Lynch Syndrome	Distinct immune and metabolic transcriptomic profiles in right and left normal colonic mucosa of Lynch Syndrome carriers
53	OP-0060	Sean Shi-An Lim	Singapore	Lynch Syndrome	Evaluating shared decision-making in cancer genetics counselling using a measure of informed choice for Lynch syndrome
54	PP-0020	Hyeon Hee Lee	South Korea	Lynch Syndrome	In vitro immune prediction model for early tumorigenesis in Lynch syndrome using colon organoids and autologous immune cells.
55	PP-0029	Francisco López	Chile	Lynch Syndrome	Prevalence and profile of germline variants from a Chilean hereditary cancer registry
56	PP-0033	Tasmyn Scriven	Singapore	Lynch Syndrome	Impact of 'Living with Lynch' Support Group Event on Patient Outcomes: A Singapore Perspective
57	PP-0042	Walaa Alshaia	United States	Lynch Syndrome	Real-World Body Mass Index Changes and Cancer Penetrance in Lynch Syndrome
58	PP-0043	Joaquín Castillo-Iturra	Spain	Lynch Syndrome	Risk Factors Of Metachronous Colorectal Cancer In Lynch Syndrome
59	PP-0044	Janina Bazalar-Palacios	Norway	Lynch Syndrome	Assessing the role and future of genetic service providers in hereditary cancer care in Latin America
60	PP-0045	Janina Bazalar-Palacios	Peru	Lynch Syndrome	Patient experience of genetic testing and diagnosis of hereditary cancer syndromes: Insights from Peru and implications for Latin America

Laguna Ballroom 3 Poster Panels

44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62

Poster Panel 42 - 53: Session A
Poster Panel 54 - 61: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 3 | GROUP 4					
63	EI-0004	Saurin Jean Christophe	France	Familial Adenomatous Polyposis	Gastric dysplasia in Familial Adenomatous Polyposis patients : endoscopic presentation and epidemiology in Western countries.
64	EI-0040	Hicham Bouchiba	Netherlands	Familial Adenomatous Polyposis	Intraductal papillary neoplasm of the bile duct in a patient with familial adenomatous polyposis: expanding the extracolonic spectrum
65	EI-0051	Benjamin Zare	United Kingdom	Familial Adenomatous Polyposis	Molecular characterisation and the cell of origin of desmoid tumours in familial adenomatous polyposis.
66	EI-0053	Anisha Sukha	United Kingdom	Familial Adenomatous Polyposis	A unique case of adenocarcinoma seeding into a desmoid tumour in a patient with familial adenomatous polyposis
67	EI-0068	Andrew Latchford	United Kingdom	Familial Adenomatous Polyposis	Life expectancy and changing causes of mortality in familial adenomatous polyposis (FAP)
68	EI-0092	Frances Victoria Que	Philippines	Familial Adenomatous Polyposis	Familial Adenomatous Polyposis in a Filipino Male With a Pathogenic APC Variant: A 15-Year Cancer-Free Follow-Up After Prophylactic Surgery and Surveillance
69	EI-0095	Yoon Sook Yee	Malaysia	Familial Adenomatous Polyposis	Genetic counselling, testing and risk management challenges for Familial Adenomatous Polyposis (FAP) in a young patient without family history of disease
70	EI-0117	Karin Álvarez	Norway	Familial Adenomatous Polyposis	Characterizing APC-Associated Polyposis: A Comprehensive Genetic Analysis from Latin America
71	EI-0128	Mathijs J. Mol	Netherlands	Familial Adenomatous Polyposis	The development of a mental health screening tool for Familial Adenomatous Polyposis (FAP); a research protocol
72	EI-0129	Mathijs J. Mol	Netherlands	Familial Adenomatous Polyposis	Mental health and unmet needs in Familial Adenomatous Polyposis: semi structured interviews with FAP patients
73	EI-0132	Ripple Man	United Kingdom	Familial Adenomatous Polyposis	Outcomes after stopping chemoprevention with non-steroidal anti-inflammatory drugs in the lower gastrointestinal tract in familial adenomatous polyposis.
74	EI-0135	Anne-Sophie Layritz	Germany	Familial Adenomatous Polyposis	Thyroid disease in familial adenomatous polyposis: results from a prospective screening cohort at the German National Center for Hereditary Tumor Syndromes
75	EI-0146	Samuel J. Klempner	United States	Familial Adenomatous Polyposis	Zolucatetide (FOG-001), a first-in-class direct β-catenin:TCF inhibitor, exhibits activity in a Familial Adenomatous Polyposis (FAP) patient with Desmoid Tumor (DT) and a preclinical FAP model
76	OP-0012	Iddo Bar-Yishay	Israel	Familial Adenomatous Polyposis	Endoscopic Resection of Large Non-Pedunculated Polyps in Hereditary Colorectal Cancer Patients- Feasibility, Safety, and Efficacy
77	OP-0019	Hicham Bouchiba	Netherlands	Familial Adenomatous Polyposis	Risk factors of gastric cancer in patients with familial adenomatous polyposis
78	OP-0030	Patrizia Pasanisi	Italy	Familial Adenomatous Polyposis	Dietary modulation of gut immuno-inflammatory profile for adenoma reduction in Familial Polyposis: study protocol and preliminary data
79	OP-0031	Hicham Bouchiba	Netherlands	Familial Adenomatous Polyposis	Endoscopic resection of gastric dysplastic lesions in familial adenomatous polyposis: a prospective international cohort study
80	PP-0005	Kazuhito Sasaki	Japan	Familial Adenomatous Polyposis	Does Sex Influence the Occurrence of Upper GI Neoplasia in Patients with Familial Adenomatous Polyposis? A Retrospective Analysis
81	PP-0006	Jessica Emadi-Cork	United Kingdom	Familial Adenomatous Polyposis	How genetic counselling intervention improves access to recommended colorectal surveillance in patients with Familial Adenomatous Polyposis (FAP).
82	PP-0023	Momoko Araki	Japan	Familial Adenomatous Polyposis	Needs Experienced by Patients Living with Familial Adenomatous Polyposis (FAP) in Their Social Lives
83	PP-0025	Diya Porwal	Singapore	Familial Adenomatous Polyposis	Oesophago-Gastro-Duodenoscopy Findings in Familial Adenomatous Polyposis: Features in a Muti-Ethnic Asian Cohort
84	PP-0032	Chrystelle COLAS	Switzerland	Familial Adenomatous Polyposis	Prevalence of APC Gene Mosaic Alterations in Patients with Unexplained Colorectal Adenomatous Polyposis or Multiple Adenomatous Polyps
85	PP-0046	Nur Hikmah Fitriyah	Singapore	Familial Adenomatous Polyposis	Bridging the genetic literacy gap: Investigating visual storytelling to enhance understanding of hereditary cancer predisposition syndromes

Laguna Ballroom 3 Poster Panels

63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85

Poster Panel 62 - 74: Session A
Poster Panel 75 - 84: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 4 | GROUP 5					
86	EI-0017	Wu Wing Kwan Claudia	Hong Kong SAR, Ch	Other Polyposis Syndromes	Peutz-Jeghers Syndrome: A case series
87	EI-0069	James Cockburn	United Kingdom	Other Polyposis Syndromes	Colonoscopic Surveillance Outcomes in PTEN Hamartoma Tumour Syndrome
88	EI-0074	Imogen Bennett	United Kingdom	Other Polyposis Syndromes	The role of PIGA in adenoma development in Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP).
89	EI-0084	Diantha Terlouw	Netherlands	Other Polyposis Syndromes	Exploring APC Mosaicism in Upper Intestinal Tract Adenomas
90	EI-0096	Jared R Hendren	United States	Other Polyposis Syndromes	Thyroid Ultrasound Surveillance for MUTYH-associated Polyposis: A Feasible Strategy for Early Cancer Detection
91	EI-0099	Jared Hendren	United States	Other Polyposis Syndromes	Expanding the spectrum: extra-colonic malignancies in MUTYH-associated polyposis
92	EI-0101	Jared Hendren	United States	Other Polyposis Syndromes	Urinary Tract Ultrasound Surveillance for MUTYH-associated polyposis: Insights from 19 Years of Clinical Practice
93	EI-0107	Khalid Mahmood	Australia	Other Polyposis Syndromes	ClinGen-InSiGHT POLE/POLD1 Variant Curation Expert Panel: variant classification guidelines and integration of tumour phenotype data
94	EI-0141	Laura Valle	Spain	Other Polyposis Syndromes	AlphaMissense outperforms other predictors for POLE and POLD1 exonuclease domain missense variant classification: Benchmarking and clinical impact
95	OP-0001	Shoko Miyahara	Japan	Other Polyposis Syndromes	Endoscopic Management in Peutz-Jeghers Syndrome: Nationwide Data from the 2nd Nationwide Survey in Japan
96	OP-0002	Amalia Nicole Nanciu	Germany	Other Polyposis Syndromes	Cost-Effective Analysis of Preventive Care vs. Non-Prevention in Peutz-Jeghers Syndrome across Europe: Insights from the PREVENTABLE Project
97	OP-0006	Stefan Aretz	Germany	Other Polyposis Syndromes	Candidate genes for unexplained Cowden syndrome
98	OP-0034	Claudia Monaco	Italy	Other Polyposis Syndromes	MUTYH-associated polyposis: phenotypic spectrum and genotype-phenotype correlations in a single-centre cohort of 170 patients
99	OP-0039	Peter Georgeson	Australia	Other Polyposis Syndromes	Mutational signature profiling of multiple colorectal polyps from unexplained polyposis cases identifies novel aetiologies
100	PP-0008	Noah Cornelis Helderman	Netherlands	Other Polyposis Syndromes	Biallelic germline inactivation of HROB causes hypogonadism and is potentially associated with polyposis predisposition
101	PP-0009	Maartje Nielsen	Netherlands	Other Polyposis Syndromes	POLD1 homozygote patient with double colon cancer and polyposis
102	PP-0013	Ryan O'Keeffe	Australia	Other Polyposis Syndromes	A novel deletion of exon 2 in RNF43 identified in an individual with colorectal cancer and a minimal serrated polyp phenotype
103	PP-0022	Jianglei Wu	Singapore	Other Polyposis Syndromes	Cancer Spectrum in Germline Monoallelic MUTYH Likely Pathogenic and Pathogenic Variant Carriers in a Singapore Cohort

Laguna Ballroom 3 Poster Panels

Poster Panel 85 - 95: Session A
Poster Panel 96 - 103: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
			ROW 4 | GROUP 6		
105	EI-0030	Gregory Idos	United States	Hereditary Gastric Cancer Syndromes	Novel presentation of a germline CDH1 mosaic variant
106	EI-0086	Bryson Katona	United States	Hereditary Gastric Cancer Syndromes	Prevalence of Helicobacter pylori and Risk Factors Among BRCA1 and BRCA2 Carriers
107	OP-0020	Hidewaki Nakagawa	Japan	Hereditary Gastric Cancer Syndromes	Germline CDH1 Variants in 10, 000 Gastric Cancer Patients in Japan
108	OP-0055	Giovana Tardin Torrezan	Brazil	Hereditary Gastric Cancer Syndromes	Germline pathogenic variants and clinical phenotype of Brazilian patients at risk for hereditary gastric cancer
109	OP-0063	Luis G Carvajal-Carmona	United States	Hereditary Gastric Cancer Syndromes	Genomic Insights into Hereditary and Early-Onset Gastric Cancer in Latino Populations
110	PP-0002	Tomomi Oka	Japan	Hereditary Gastric Cancer Syndromes	A case with hereditary diffuse gastric cancer harboring a novel germline CDH1 pathogenic splicing variant identified by the Combined Long Amplicon Sequencing (CoLAS)
111	PP-0017	Manasadevi Karthikeyan	Singapore	Hereditary Gastric Cancer Syndromes	Prevalence of germline pathogenic variants in hereditary cancer predisposing genes in patients with gastric cancer in an Asian cohort.
112	PP-0024	Minmin Li	Australia	Hereditary Gastric Cancer Syndromes	Genetic Counselling for GAPPS: A Single Australian Institution Experience
113	EI-0016	Erez Hasnis	Israel	Hereditary Pancreatic Cancer Syndromes	Comparing Pancreatic Cancer Screening Efficacy in Different Genetic and Familial Undications
114	EI-0078	Linda M. Polfus	United States	Hereditary Pancreatic Cancer Syndromes	Heterogeneity of Pancreatic Cancer Risk Across Germline Susceptibility Genes and Sex
115	EI-0094	Anjeli Manam	United States	Hereditary Pancreatic Cancer Syndromes	Blood-based Testing Practices Amongst High-Risk Individuals Undergoing Pancreatic Cancer Surveillance Within the International Pancreatic Cancer Early Detection (PRECEDE) Consortium
116	PP-0001	Colas Chrystelle	France	Hereditary Pancreatic Cancer Syndromes	BRCA1-2 germline pathogenic variants associated with hepatobiliary cancer: a retrospective study
117	PP-0021	Monika Koudová	Czech Republic	Hereditary Pancreatic Cancer Syndromes	One in Ten: Clinically actionable germline variants in Czech pancreatic adenocarcinoma
118	PP-0031	Ben-Yehoyada, Merav	Israel	Hereditary Pancreatic Cancer Syndromes	Insights on Surveillance for High-Risk Pancreatic Cancer Individuals
119	EI-0070	Laura Valle	Spain	Novel Genes in Hereditary GI Tumours	Constitutional epimutation in LTBP4 as potential driver of early-onset colorectal cancer and pulmonary emphysema
120	EI-0076	Laura Valle	Spain	Novel Genes in Hereditary GI Tumours	Genetic determinants of early-onset colorectal cancer: A cohort study on rare and common variants
121	EI-0105	Ruby Clarissa Sutopo	Singapore	Novel Genes in Hereditary GI Tumours	Hepatic manifestations in patients with heterozygous FH variants: A Case Series
122	EI-0139	Frances Victoria F. Que, MD	Philippines	Novel Genes in Hereditary GI Tumours	Young patient with colorectal cancer and a germline BRCA2 pathogenic variant
123	OP-0046	Peh Yean Cheah	Singapore	Novel Genes in Hereditary GI Tumours	NR0B2, an orphan nuclear receptor, could be a novel tumor suppressor associated with metabolic manifestation in microsatellite-stable, APC mutation-negative familial colorectal carcinomas.

ROW 4

Laguna Ballroom 3 Poster Panels

Poster Panel 104 - 114: Session A
Poster Panel 115 - 122: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 4 | GROUP 7					
124	EI-0109	Alysha Prisc	Australia	Microbiome and Environmental Modifiers	Unexplained familial early-onset colorectal cancer: determining a shared aetiology by tumour mutational signature profiling
125	EI-0033	Aasem Abu Shtaya	Israel	Germline Mosaicism in Hereditary GI Tumours	Co-occurrence of MSH6 variant and MLH1 constitutional epimutation in a young colorectal cancer patient
126	EI-0035	Shlomi Cohen	Israel	Pediatric Hereditary GI Tumour Syndromes	Clinical and Genetic Features of Gastrointestinal Polyposis Syndromes in Children: Results from a Nationwide Multicenter Cohort
127	EI-0077	Nicholas Fernandez	Canada	Pediatric Hereditary GI Tumour Syndromes	Hypermutation patterns shape tumorigenesis and immunotherapy response in mismatch repair deficient glioma
128	EI-0136	Tomomitsu Sado	Japan	Pediatric Hereditary GI Tumour Syndromes	Diagnostic and therapeutic utility of small bowel endoscopy in children with hamartoma polyposis syndrome
129	OP-0056	Gabriel Capellá	Spain	Pediatric Hereditary GI Tumour Syndromes	Modelling gliomagenesis in Constitutional Mismatch Repair Deficiency syndrome
130	OP-0059	Marta Pineda	Spain	Pediatric Hereditary GI Tumour Syndromes	Microsatellite instability patterns in follow-up samples from CMMRD patients
131	PP-0011	Dr Warren Hyer	United Kingdom	Pediatric Hereditary GI Tumour Syndromes	Combined PTEN and BMPR1A gene variants – manifestations , clinical course and outcome
132	PP-0014	Lin Zhenhan Isaac	Singapore	Pediatric Hereditary GI Tumour Syndromes	Whole Genome Sequencing Identifies Incidental GI-Associated Germline Variants in Childhood Cancers

ROW 4

Laguna Ballroom 3 Poster Panels

Poster Panel 123 - 127: Session A
Poster Panel 128 - 132: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 5 | GROUP 8					
134	EI-0034	Aasem Abu Shtaya	Israel	Health Policy and Equity	The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing
135	EI-0058	Jeanette Yuen	Singapore	Health Policy and Equity	Genetic Discrimination: a review of current policy approaches
136	EI-0082	Roshani Patel	United Kingdom	Health Policy and Equity	Three year experience of the UK national Hereditary Gastrointestinal Polyposis Syndromes Rare Disease Collaborative Network MDT
137	OP-0053	Rebecca Caeser	Singapore	Health Policy and Equity	Building a Precision Medicine Ecosystem: The Design of Singapore's Clinical Implementation Pilots
138	PP-0026	Tan Yu Bin	Singapore	Health Policy and Equity	National Survey on Knowledge and Service Gaps in Hereditary Gastrointestinal Cancers in Singapore
139	EI-0008	Anthony Vladimir Campos Se	Brazil	Studies in Asia and Underrepresented Populations	Tumor mutational signatures in Brazilian patients with high-risk colorectal cancer: An Innovative Approach to Exploring the Reclassification of Variants of Uncertain Significance and Genetic Causes of Unexplained Polyposis and Multiple Tumors
140	EI-0014	Hong-Min Ahn	South Korea	Studies in Asia and Underrepresented Populations	Hereditary cancer susceptibility gene mutations in young colorectal cancer patients under age 40
141	EI-0032	Aasem Abu Shtaya	Israel	Studies in Asia and Underrepresented Populations	The genetic landscape of Lynch syndrome in the Israeli population
142	EI-0048	Chayanin Kasidajpong	Thailand	Studies in Asia and Underrepresented Populations	Clinicopathological features and genetic characteristics using whole genome sequencing in inherited colorectal cancer patient in Southern Thailand
143	EI-0055	Rutharra Ghayadthri Manisek	Singapore	Studies in Asia and Underrepresented Populations	Variant reclassification in hereditary cancer genes leveraging Asian population data.
144	EI-0057	Jeanette Yuen	Singapore	Studies in Asia and Underrepresented Populations	Adherence of patients with hereditary cancer syndromes to recommended scopes: a 10-year experience in Singapore
145	EI-0059	Jeanette Yuen	Singapore	Studies in Asia and Underrepresented Populations	Multi-locus Inherited Neoplasia Alleles Syndromes in Cancer: An updated review and implications for clinical practice
146	EI-0106	Caitlin Nicole Samy Victoria	Singapore	Studies in Asia and Underrepresented Populations	Navigating Hereditary Cancer Risk in Singaporean Families: Understanding What Influences Genetic Testing Uptake
147	PP-0003	Tan Yu Bin	Singapore	Studies in Asia and Underrepresented Populations	H.Pylori, Gastric Cancer and Its Precursors in Homologous Recombinant Deficiency Gene Carriers – Gaps in Current Practice in a Multi-ethnic Asian Population
148	PP-0016	Tatsuro Yamaguchi	Japan	Studies in Asia and Underrepresented Populations	Hereditary Gastrointestinal Tumor Syndromes in Japanese Population
149	PP-0034	Mashu Futagawa	Japan	Studies in Asia and Underrepresented Populations	Germline Pathogenic Variants in MMR Genes Detected by Matched-Pair CGP: Two Cases Highlighting the Need for Structured Protocols
150	PP-0036	Li Shao-Tzu	Singapore	Studies in Asia and Underrepresented Populations	Detection of incidental findings from multigene panel testing for hereditary cancer syndromes in Asia
151	PP-0040	Katrina R. Ellis	United States	Studies in Asia and Underrepresented Populations	Religion and spirituality in family communication about cancer genetic testing among African Americans



Poster Pane; 133 - 142: Session A
Poster Panel 143 - 150: Session B

Poster Display Panels

Poster Panel No.	Submission ID	First Author	Country/Region	Abstract Topic	Abstract Title
ROW 5 | GROUP 9					
152	EI-0079	Hashini Kristhorubaduge	Australia	Artificial Intelligence in Risk Assessment	Helixor: An AI-powered Automated literature and supplement scanner for Variant assessment
153	OP-0061	Matthias Kloor	Germany	Artificial Intelligence in Risk Assessment	Evaluating the potential of artificial intelligence-based algorithms to predict Lynch syndrome from histopathology images of mismatch repair-deficient colorectal cancer
154	EI-0081	Kelly Kohut	United Kingdom	Digital Health in Hereditary GI Cancer	Digital health management using Lynch Choices: implementation of a codesigned information hub and decision support intervention for Lynch syndrome
155	EI-0138	Michelle Jacobs	United States	Digital Health in Hereditary GI Cancer	Refining Risk: Higher PREMM5 Thresholds for Identifying Advanced Colorectal Neoplasia
156	OP-0008	Hiroto Narimatsu	Japan	Digital Health in Hereditary GI Cancer	Development and International Implementation of an AI-Powered Genetic Counseling System for Multiple Hereditary Cancer Syndromes: From Japanese Clinical Validation to English-Language Singapore Expansion
157	OP-0051	Rebecca Caeser	Singapore	Digital Health in Hereditary GI Cancer	Improving the Patient Journey for Hereditary Conditions: Towards Asia's first precision care model for cascade testing
158	EI-0042	Alessandro Mannucci	Italy	Implementation Science in Hereditary Cancer	Germline Multigene Panel Testing For Colorectal Cancer
159	EI-0062	Marta Puzzono	Italy	Implementation Science in Hereditary Cancer	Financial Distress Among Young Adults With Early-onset Gastrointestinal Cancers: A Call To Action
160	EI-0071	Marta Puzzono	Italy	Implementation Science in Hereditary Cancer	Diet and lifestyle as associated factors in early-onset colorectal cancer: Preliminary data from the DEMETRA study
161	EI-0090	Kevin Monahan	United States	Implementation Science in Hereditary Cancer	Diagnostic Accuracy of Fecal Occult Blood Testing for Surveillance in High-Risk Colorectal Cancer Populations: A Systematic Review and Meta-analysis
162	PP-0027	Claresta Yeo Chyi Maey	Singapore	Implementation Science in Hereditary Cancer	High-throughput Image-based Phenotypic Profiling of Immune Cells for Functional Assessment and Pathogenicity Prediction of Germline Variants
163	EI-0061	Tiffany Lim	Singapore	Non-Physician Providers in Cancer Management	Exploring Genetic Counsellor Communication in Hereditary Cancer Management: A Conversation Analysis Approach
164	OP-0007	Jessica Emadi-Cork	United Kingdom	Non-Physician Providers in Cancer Management	The role of the genetic counsellor in the multidisciplinary management of patients and families with Hereditary Polyposis Syndromes in the North West of England: to transition and beyond.
165	PP-0010	Hiroko Fujita	Japan	Non-Physician Providers in Cancer Management	The Current Status of Consultation on Hereditary Cancer Predisposition Syndromes at Cancer Information Support Centers in Japan
166	PP-0015	Kana Yamatogi	Japan	Non-Physician Providers in Cancer Management	Multidisciplinary Roles of Genetic Counselors in the Management of Hereditary Colorectal Cancer Syndromes: Our Practice at A Core Facility in Japan

ROW 5

Laguna Ballroom 3 Poster Panels

Poster Panel 151 - 158: Session A
Poster Panel 159 - 169: Session B

Pre-Congress Workshops

Endoscopy in Hereditary GI Cancers

Details	Date: 4 March 2026 Time: 09:00 to 12:00
Venue	Dusit Thani Laguna Singapore, Level 5, Albatross & Birdie
Format	This workshop will combine didactic lectures, case-based discussions, and interactive sessions to ensure active learning and practical application of endoscopy and surgical concepts in the field of hereditary GI cancers.
Synopsis	A national survey on knowledge and service gaps in hereditary gastrointestinal cancers among healthcare professionals in Singapore noted significant knowledge gaps in the identification and management of such patients. This half day review course has been meticulously designed to bridge the knowledge gap and enhance the identification, management and surveillance of such patients. We will explore key topics in endoscopy phenotypes, surgical advances and techniques and small bowel endoscopy of hereditary GI cancer patients, through a combination of expert-led lectures and case discussions.
Synopsis	By the end of the workshop, participants will be able to: 1. Be confident in endoscopic phenotypes of hereditary GI cancers: • Identify key endoscopic features of hereditary gastrointestinal cancer syndromes (e.g., FAP, Lynch syndrome, Peutz-Jeghers, serrated polyposis). • Differentiate hereditary cancer–associated lesions from sporadic polyps and other mimickers. • Recognise clinical and endoscopic red flags that should prompt referral for genetic testing. 2. Understand surgical advances & techniques in hereditary GI cancers: • Compare surgical approaches for hereditary versus sporadic GI cancers, including extent of resection and organ-preserving strategies. • Describe the role of novel surgical platforms (e.g., single-port robotic surgery) in the management of hereditary cancer patients. • Apply principles of individualised surgical planning for hereditary cancer patients, balancing oncologic safety with function preservation. Appreciate small bowel surveillance and resection in Peutz–Jeghers (PJ) patients • Outline surveillance protocols for small bowel polyps in PJ patients. • Demonstrate techniques for safe endoscopic resection of large or complex small bowel polyps. • Anticipate and manage technical challenges and complications in small bowel surveillance and polyp removal.
Target Participants	Gastroenterologists, Surgeons, Trainees
Speakers	 Tan Yu Bin, Singapore  Andrew Latchford, United Kingdom  Matthew Kalady, United States  Evelien Dekker, Netherlands

Pre-Congress Workshops

	Time	Description/Title	Speakers
Schedule	09:00 – 09:30	Endoscopic phenotypes of hereditary GI cancers	Tan Yu Bin Singapore
	09:30 – 10:00	Case based / video discussions	Andrew Latchford United Kingdom
	10:00 – 10:30	Surgical advances & techniques in hereditary GI cancers	Matthew Kalady United States
	10:30 – 11:00	Case based / video discussions	Andrew Latchford United Kingdom
	11:00 – 11:30	Small bowel endoscopy in hereditary GI cancers	Evelien Dekker Netherlands
	11:30 – 12:00	Case based / video discussions	Evelien Dekker Netherlands

Pre-Congress Workshops

Hereditary Gastrointestinal (GI) Cancer Masterclass

Details	Date: 4 March 2026 Time: 09:00 to 12:00
Venue	Dusit Thani Laguna Singapore, Level 3, Laguna Ballroom
Synopsis	The Hereditary Gastrointestinal (GI) Cancer Masterclass is a focused, expert-led educational session designed clinicians, trainees, researchers, nurses, genetic counsellors and anyone interested in strengthening their understanding of hereditary GI cancer syndromes. This masterclass will introduce the fundamental principles of hereditary GI cancers, from recognising clinical patterns and understanding genetic mechanisms, to interpreting molecular test results and applying management strategies in practice. Participants will also gain insight into multidisciplinary care approaches through interactive case discussions. Whether you are a clinician wanting to better identify hereditary risk, a researcher exploring translational applications, or a trainee seeking structured learning in hereditary oncology, this session provides a practical and engaging foundation to complement the broader InSiGHT 2026 scientific programme.
Objectives	By the end of the masterclass, participants will be able to: 1. Understand the principles of hereditary GI cancer syndromes and their genetic basis. 2. Recognise clinical features and family history patterns that suggest an inherited cancer predisposition. 3. Describe the approach to genetic testing and variant interpretation for common hereditary GI syndromes. 4. Outline current surveillance and management recommendations for affected individuals and at-risk relatives. 5. Discuss real-world cases and multidisciplinary perspectives in diagnosis, counselling, and clinical decision-making.
Target Participants	Clinicians, Trainees, Researchers, Nurses, Genetic Counsellors, and anyone interested to strengthen their understanding of hereditary GI cancer syndromes.
Speakers	 Francesc Balaguer, Spain  Megan Hitchins, United States  Susan Clark, United Kingdom  Manasa Karthikeyan, Singapore  Heather Hampel, United States  Sonia Kupfer, United States

Pre-Congress Workshops

	Time	Description/Title	Speakers
Schedule	09:00 – 09:30	Hereditary GI Genomics	Heather Hampel Canada
	09:30 – 10:00	Epimutations in Hereditary GI cancers	Megan Hitchins United States
	10:00 – 10:30	Management of Hereditary GI cancers	Susan Clark United Kingdom
	10:30 – 10:50	Break	
	10:50 – 11:30	Case Studies	Sonia Kupfer United States Francesc Balaguer Spain

Satellite Breakout Sessions

Title	Young-InSiGHT Padel Event
Details	Date: 4 March 2026 Time: 20:00 – 22:00 Venue: Ricochet Padel @ Laguna, Laguna National Golf Resort Club
Agenda	Start your InSiGHT 2026 experience with energy, movement, and meaningful connections at the inaugural Young-InSiGHT Padel Event. Join colleagues and fellow delegates for a refreshing morning of padel and networking at the beautiful Laguna National Golf Resort Club. Whether you're a seasoned player or completely new to the sport, this informal session is designed to be welcoming, social, and fun. This event offers the perfect opportunity to meet peers, spark conversations, and build connections in a relaxed, active setting before the main congress programme begins. No registration is required, simply come along and join in. Kick off your congress with a dynamic blend of sport, community, and conversation. We look forward to seeing you on the court.

Title	Young-InSiGHT Breakfast Session
Details	Date: 5 March 2026 Time: 07:30 – 08:20 Venue: Laguna Ballroom
Agenda	Join us for an engaging and energising start to the day at the Young-InSiGHT Breakfast Session during InSiGHT 2026. Designed as an informal and welcoming gathering, this breakfast session offers a relaxed space to connect with colleagues, share ideas, and build new professional relationships. Whether you're reconnecting with familiar faces or meeting peers for the first time, this session provides the perfect setting for meaningful conversations before the day's scientific programme begins. Enjoy a comfortable atmosphere, good company, and a refreshing start to your congress morning! No registration is required, simply come along and join in.

Satellite Breakout Sessions

Title	ClinGen Vcep Breakout Session
Details	Date: 5 March 2026 Time: 07:30 – 08:20 Venue: Albatross & Birdie Chairs: Marc Greenblatt, United States Sharon Plon, United States
Agenda	InSiGHT variant curation activities began in the late 2000's with work on variants in the mismatch repair MMR genes. The Insight Variant Interpretation Committee (VIC) first harmonized multiple databases and then in the early 2010's developed rules to classify variants. When the US National Institutes of Health (NIH) developed the Clinical Genome Resource (ClinGen) they encouraged active classification committees to develop Variant Curation Expert Panels (VCEPs) and the opportunity to apply for funding. The InSiGHT-ClinGen VCEP was awarded a grant to expand VCEP activities to other hereditary colon cancer and polyposis genes. This session will review the inSIGHT-ClinGen VCEP activities of the last 5 years, including publication of classification guidelines for APC, and look forward to new activities addressing new genes, new classification rules, and new technologies.
Speakers	 Marc Greenblatt, United States  Sharon Plon, United States

Title	Genetic Counsellors Roundtable
Details	Date: 5 March 2026 Time: 07:30 – 08:20 Venue: Eagle Boardroom Chairs: Manasa Karthikeyan, Singapore Brandie Leach, United States Marie Met-Domestici, Switzerland
Agenda	This roundtable session will provide a forum for genetic counsellors to engage in discussion on how the profession is evolving across different healthcare systems and regions. Drawing on perspectives from international and cross-continental practice settings, the session will explore variation in clinical practice, regulatory environments, and professional roles, alongside broader considerations related to technological innovation, career development, research translation, and ethical practice. Brief opening remarks from the facilitators will introduce key areas for reflection and guide a moderated, roundtable-style discussion on current and emerging issues relevant to genetic counselling.
Speakers	 Manasa Karthikeyan, Singapore  Marie Met-Domestici, Switzerland  Brandie Leach, United States

Satellite Breakout Sessions

Title	Get to Know Journal of Gastropenterology and Hepatology (JGH) Session
Details	Date: 5 March 2026 Time: 15:40 – 16:10 Venue: Albatross & Birdie Rakesh Aggarwal, Chair, Journal of Gastroenterology and Hepatology Foundation
Agenda	Familial Cancer is a unique multidisciplinary journal which covers all aspects of hereditary cancer of interest to the clinician, geneticist, psychosocial worker, surgical and medical oncologist. It encompasses all aspects of hereditary cancer. Coverage includes epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counseling, and the health economics of familial cancer.
Speaker	 Rakesh Aggarwal, India

Title	InSiGHT Asia Chapter / ICaN Meeting
Details	Date: 6 March 2026 Time: 07:30 – 08:20 Venue: Albatross & Birdie Chairs: Joanne Ngeow, Singapore Finlay Macrae, Australia
Agenda	ICaN Asia and InSiGHT Asia Chapter ICaN Asia, established in 2025, aims to improve health outcomes for individuals and families affected by hereditary cancers across the Asia-Pacific region. This segment will introduce the InSiGHT Asia Chapter and ICaN Asia, highlighting their shared vision to advance hereditary cancer research and care across the region. The discussion will cover variant curation in the Asian context, regional collaboration priorities, and future directions, while emphasizing how both initiatives complement each other in strengthening data sharing, research, education, and network-building across Asia. Participants will also be invited to express interest in membership and ongoing engagement.
Speakers	 Finlay Macrae, Australia  Joanne Ngeow, Singapore

Satellite Breakout Sessions

Title	CMMRD Workshop
Details	Date: 6 March 2026 Time: 12:40 – 14:00 Venue: Albatross & Birdie Chairs: Uri Tabori, Canada Anirban Das, Canada Lucie Stengs, Canada
Agenda	This in-person workshop will highlight the latest advances in replication repair deficiency (RRD), with a focus on constitutional mismatch repair deficiency (CMMRD). Topics include new diagnostic criteria and surveillance tools (including liquid biopsy), clinical and genomic landscapes of CMMRD, CNS and extracranial RRD-associated cancers, immunotherapy and combinational immune-based treatments, novel insights into RRD carcinogenesis, emerging CMMRD cancer vaccines, patient registries, global collaboration, and (if time allows) interactive case discussions. The meeting aims to foster international collaboration and accelerate translation from discovery to clinical care.
Speakers	 Uri Tabori, Canada  Lucie Stengs, Canada  Anirban Das, Canada

Title	Get to Know Familial Cancer Session
Details	Date: 6 March 2026 Time: 15:30 – 16:00 Venue: Albatross & Birdie Gabriel Capellá, Editors-in-Chief, Familial Cancer Hans Vasen, Editors-in-Chief, Familial Cancer
Agenda	More information coming soon
Speakers	 Gabriel Capellá, Spain  Hans Vasen, The Netherlands

Satellite Breakout Sessions

Title	InSiGHT General Meeting		
Details	Date: 6 March 2026 Time: 17:40 – 18:20		
Agenda	Time	Description	Speakers
	17:40	Apologies Note of passing: i. Joji Utsonomia ii. Charis Ng	
	17:42	Minutes of last meeting iii. Business arising	Gabriel Capella
	17:45	Honorary Secretary's report	Andrew Latchford
	17:50	Honorary Treasurer's report	Laura Valle
	17:55	Presentation of Honorary Life Membership	Gabriel Capella
	18:05	Results of Council Election	Gabriel Capella
	18:10	Handover of InSiGHT Chair	Gabriel Capella Joanne Ngeow
	18:15	2028 Biennial Meeting in Chicago	Sonia Kupfer
	18:20	Any other business	
Speakers	 Joanne Ngeow, Singapore	 Andrew Latchford, United Kingdom	
	 Gabriel Capellá, Spain	 Laura Valle, Spain	

Satellite Breakout Sessions

Title	EOCRC Hour
Details	Date: 7 March 2026 Time: 08:00 – 08:50 Venue: Laguna Ballroom Chairs: Daniel Buchanan, Australia Alvin Ng, Singapore
Agenda	More information coming soon
Speakers	 Daniel Buchanan, Australia  Alvin Ng, Singapore

Title	Collab Lab @ InSiGHT
Details	Date: 7 March 2026 Time: 08:00 – 08:50 Venue: Albatross & Birdie Chair: Joanne Ngeow, Singapore
Agenda	The Collab Lab @ InSiGHT is a dedicated meeting session designed to catalyse meaningful, cross-institutional and international collaborations in hereditary gastrointestinal cancer research. This interactive forum moves beyond traditional lecture-style presentations to create an active space for idea exchange, partnership building, and project incubation. Recognising that impactful research often begins with the right collaborators in the room, this session provides investigators with an opportunity to briefly “advertise” ongoing or planned studies at the start of the meeting. These concise pitches will highlight research questions, unmet needs, methodological approaches, and specific collaboration gaps. The second half of the session transitions into a structured roundtable format, where interested participants can engage directly with project leads to explore potential roles, share complementary expertise, and discuss feasibility, funding pathways, and next steps.
Speakers	 Joanne Ngeow, Singapore

Satellite Breakout Sessions

Title	Living with Lynch Patient Conference (By Invite Only)	
Details	Date: 7 March 2026 Time: 13:00 – 16:00 Venue: Albatross & Birdie	
Agenda	Time	Description
	13:00 - 13:15	Opening Remarks for Living for Lynch
	13:15 - 14:00	Lunch with Experts from InSiGHT with Q&A session
	14:00 - 14:45	Human Library
	14:45 - 15:00	Short Break
	15:00 - 15:15	Topic 1: Power of Patient Centred Research and Lynch Choices Kelly Kohut, Lead Consultant Genetic Counsellor, United Kingdom
	15:15 - 15:30	Topic 2: Genetic Testing and Insurance Jeanette Yuen, Principal Genetic Counsellor, Singapore
	15:30 - 15:45	Topic 3: Nurturing Health Through Diet Wen Lynn Teong, Senior Dietician, Singapore
	15:45 - 16:00	Q&A session
	16:00	Closing Remarks
Speakers	 Kelly Kohut, United Kingdom  Jeanette Yuen, Singapore	 Wen Lynn Teong, Singapore

Sponsored Symposium

aws

AI in Precision Medicine on AWS

Details	Date: 5 March 2026 Time: 15:40 – 16:10
Venue	Laguna Ballroom
Synopsis	This Meet-the-Expert session explores how AI is advancing precision medicine, from scalable cloud platforms to real-world oncology applications. The session begins with an overview of AI in Precision Medicine on AWS, highlighting how cloud-native AI enables secure, scalable analysis of multi-omics and clinical data and supports the translation of research innovations into practice. This is followed by a use case presented by Dr. Mai Chan Lau on Bridging AI, Spatial Omics and Precision Oncology on AWS. In this talk, Dr Lau will first highlight how advanced spatial omics technologies have deepened our understanding of the tumor–immune microenvironment, and share representative studies demonstrating how spatial profiling can reveal novel biomarkers that are critical for patient stratification and treatment decision-making. She will introduce Digital Immune Reporter, an AI platform which aims to enable scalable spatial analysis and biomarker discovery directly from routine histology (H&E) images. Built on AWS, the platform is designed to support scalability, accessibility, and seamless deployment across institutions and clinical environments. Finally, Dr Lau will discuss the potential translational impact of the Digital Immune Reporter across biomedical research, clinical trials, diagnostics, and ultimately, patient care.
Objectives	• Understand how AI and cloud platforms enable scalable, secure precision medicine workflows across multi-omics and clinical data. • Learn from a real-world precision oncology use case integrating AI and spatial omics through the Digital Immune Reporter. • Gain insight into how AI-driven approaches can translate research innovations into actionable clinical and translational outcomes.
Speakers	 Charlie Lee, Singapore Charlie Lee is the Genomics Industry Lead for APJ at AWS, with over 20 years of experience spanning research and industry. Holding a Ph.D. in Bioinformatics from the National University of Singapore, he pioneered pathogen detection technologies during the SARS and H1N1 outbreaks at the Genome Institute of Singapore. In the industry, Dr Lee held senior roles at Vela Diagnostics, leading a team to develop and launch over 40 molecular diagnostic products, including the first CE-IVD NGS-based oncology test and the first FDA-approved NGS-based HIV genotyping test. Dr Lee also contributed to an award-winning genomics health platform at Human Longevity Inc, a San Diego-based genomics health intelligence company founded by Prof Craig Venter. At AWS, Dr Lee drives genomics strategies and engagements across APJ, supporting precision medicine initiatives and leveraging cloud and AI to accelerate innovation in healthcare and improve patient outcomes.

Sponsored Symposium

aws

<table>
<tr><td>Speakers</td><td colspan="3"> 
Mai Chan Lau, Singapore
Mai Chan Lau earned her PhD from the National University of Singapore, focusing on high-performance GPU research. She began her postdoctoral training at the Singapore Immunology Network (ASTAR), focusing on single-cell immunology bioinformatics. Following this, she moved to Boston, USA, where she leveraged AI and machine learning for Molecular Pathological Epidemiology (MPE) studies, using tissue-based multi-marker technology at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School. In 2021, she returned to Singapore and joined the Institute of Molecular and Cell Biology (ASTAR), expanding her research to spatial transcriptomics and AI. In November 2022, she established her own laboratory at the Bioinformatics Institute (ASTAR), concentrating on advanced spatial multi-omics studies using AI and quantum computing. Concurrently, she leads the Computational Immunology Platform at the Singapore Immunology Network (ASTAR).</td></tr>
<tr><td rowspan="3">Schedule</td><td>Time</td><td>Description/Title</td><td>Speaker</td></tr>
<tr><td>15:40 – 15:50</td><td>AI in Precision Medicine on AWS</td><td>Charlie Lee
Singapore</td></tr>
<tr><td>15:50 – 16:10</td><td>Use Case:
Bridging AI, Spatial Omics and Precision Oncology: Digital Immune Reporter</td><td>Mai Chan Lau
Singapore</td></tr>
</table>

Sponsored Symposium

illumina®

Diving deeper into the genome with Illumina Constellation Mapped Reads

Details	Date: 5 March 2026 Time: 10:10 – 10:40
Venue	Laguna Ballroom
Synopsis	This session will showcase the latest advances in Illumina's trusted NGS technology, designed to deliver deeper genomic insights critical for clinical research. Discover how Constellation technology enables high-resolution detection of complex variants, including structural variation and haplotype phasing key factors in understanding disease mechanisms. Hear directly from industry experts on the science behind this approach and see how it has been successfully applied in a clinical research setting to improve detection of Lynch Syndrome, offering practical strategies for enhancing diagnostic accuracy and patient outcomes.
Objectives	• Understand the principles and advantages of Constellation-mapped long-read sequencing. • Learn about the technical features and performance of the Constellation workflow. • Gain practical insights from a case study on Lynch Syndrome demonstrating successful application in a research setting.
Speakers	 Simeen Malik, Singapore Simeen Malik is a Director, Bioinformatics at Illumina, based in Singapore, where she oversees the Singapore Bioinformatics teams responsible for developing and sustaining Illumina software solutions within Illumina's R&D organization. She leads a bioinformatics data science team within the BioInsight group. Her work enables the creation of large clinical genomic datasets and the application of advanced analytical methods, including machine learning and statistical approaches, to support decision making across pre clinical and clinical programs. She also provides bioinformatics and end-to-end expert knowledge to support to all regional large national Genomics initiatives, such as PRECISE among others. Prior to Illumina, Simeen was an Associate Director in Scientific Informatics at Merck Research Laboratories IT (MSD), leading local bioinformatics for oncology and auto immunity trials and product managing a global cloud initiative for cytometry research across seven sites. She has deep experience in single cell RNA seq, including pipeline design, data and metadata curation, and interactive visualization platforms. At Duke NUS, she helped establish POLARIS—Southeast Asia's first CAP certified NGS lab—and the SingHealth Exome Consortium, delivering clinical reporting and population scale genomic resources. Her research contributions include the TCGA breast cancer study and a body of peer reviewed work in Nature, Genome Biology, Journal of Molecular Diagnostics and other outlets. Simeen earned her Ph.D. at Baylor College of Medicine and her B.S. at The University of Texas at Austin.  **Alvin Ng, Singapore** Dr Alvin Ng is the Dean's postdoctoral fellow in Lee Kong Chian School of Medicine working on using cutting-edge sequencing methodologies to understand the mutational processes underlying a variety of cancers. He recently joined Prof Joanne Ngeow's laboratory to study cancers associated with DNA repair defects in colorectal, breast and ovarian cancers. Alvin was trained in computational biology and genomics in his PhD in Duke-NUS Medical School studying liver cancers exposed to carcinogenic compounds associated with plans from the genus Aristolochia and helped develop computational tools to detect mutational signatures in patient tumours. In his postdoctoral training in the Early Cancer Institute, Cambridge. He is focused on using a combination of short and long sequencing methods to detect mutational processes associated with DNA repair defects and to understand how complex rearrangements arise in cancers. His recent work focused on the biology of complex extrachromosomal circles and large structural variants in esophageal cancers that are potent drivers or cancer evolution.

Sponsored Symposium

illumina®

	Time	Description/Title	Speakers
Agenda	10:10 – 10: 15	Welcome and speaker introduction	Joanne Ngeow Singapore
	10:15 – 10:25	Technology Overview Constellation Mapped Reads – an exciting new approach to obtain deeper insights into the genome	Simeen Malik Singapore
	10:25 – 10:35	Management of Hereditary GI cancers	Alvin Ng Singapore
	10:35 – 10:40	Wrap-Up	

Sponsored Symposium

PacBio

Evaluating PacBio Long Read Sequencing for Resolving Cancer Predisposition Variants in Singapore	
Details	Date: 6 March 2026 Time: 10:30 – 11:00
Venue	Laguna Ballroom
Speaker	 Alvin Ng, Singapore

Sponsored Symposium

Oxford Nanopore Technologies

Reveal More Cancer Biology With Ultra-rich Oxford Nanopore Sequencing Data

Details	Date: 6 March 2026 Time: 15:40 – 16:10
Venue	Laguna Ballroom
Synopsis	The genetic underpinnings of cancer are diverse and contain many types of genomic aberration. Accurate detection of genetic variants is essential but often limited by standard-of-care sequencing methods, which can miss complex structural variants (SVs), intronic regions, and epigenetic modifications. Now, with Oxford Nanopore technology, researchers are going beyond next-generation sequencing (NGS), generating sequencing reads of any length, including ultra-long reads (>4 Mb achieved) that can span complex genomic regions. This, combined with integrated base modification detection, and real-time results, means that nanopore oncology sequencing delivers a streamlined and rapid solution for complete characterisation of cancer and tumour samples.
Objectives	In this session, you will learn about Oxford Nanopore hereditary cancer panel, enabled through adaptive sampling, a real-time, on-device enrichment method unique to Oxford Nanopore sequencing. How it enables comprehensive detection of single nucleotide variants (SNVs), insertions/deletions (indels), SVs, pseudogenes, repetitive regions, direct methylation profiling, alongside low-pass whole-genome coverage to enable copy number variant detection in a flexible workflow to characterise variants in hereditary cancer susceptibility genes. You will hear real world performance of the panel, its efficiency and variant detection accuracy, and how laboratories can achieve faster, more cost-effective, and comprehensive genetic insights to support precision oncology.
Speakers	 Manop Pithukpakorn, Thailand Manop Pithukpakorn is an internist, clinical and molecular geneticist. He is currently a Professor of Medicine at the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Dr. Pithukpakorn received his medical degree from the Faculty of Medicine Siriraj Hospital, Mahidol University, residency training in Internal Medicine from the University of Illinois Chicago, and fellowship in Clinical Genetics and Molecular Genetics from the National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), USA. Dr. Pithukpakorn's current research projects are genomic investigations in various Mendelian disorders and Thailand Cancer Precision Medicine; by utilizing genome sequencing technology, computational analysis, systems biology and high-throughput drug screening for comprehensive studies of various cancers in Thai population. Genomics Thailand Initiative is the first inter-ministerial project aiming to implement genomic medicine into national healthcare system and build a population-level genome database. The project will utilize genome sequencing and other genome technology for healthcare service in 5 main areas including cancers, rare diseases, pharmacogenomics, infectious diseases and non-communicable diseases. Dr. Pithukpakorn is the initiative's head of research and development working group and is overseeing cancer program of Genomics Thailand.

Sponsored Symposium

Oxford Nanopore Technologies

Speakers	 **Lei Tong, Singapore** Lei leads the APAC Sales Specialist organisation, driving commercial strategy and execution across diverse research and clinical genomics markets throughout Asia-Pacific. She oversees segment development in genetic disease, oncology, infectious disease, and large-scale population genomics, working closely with regional teams to accelerate adoption of long-read sequencing and deliver scalable regional growth.		
Schedule	**Time**	**Description/Title**	**Speaker**
	15:40 – 15:50	Session Opening & Introduction	Lei Tong Singapore
	15:50 – 16:05	Close the Gap in Cancer Genomics with Ultra-Rich Oxford Nanopore Sequencing Data	Mai Chan Lau Singapore
	16:05 – 16:10	Q&A	All

Social Programmes

All registered attendees and exhibitors are cordially invited to the following Social Programmes:

Welcome Reception

Date: 4 March 2026
Time: 18:00 - 19:30
Venue: The Nest, Dusit Thani Laguna, Singapore
Dress Code: Smart Casual

Congress Dinner

Date: 6 March 2026
Time: 19:00 - 22:00
Venue: Hopscotch (Gardens By The Bay)
Address: 18 Marina Gardens Dr, #01-21 Bayfront Plaza, Singapore 018953
Dress Code: Smart Casual

Transportation is available from Congress venue to Congress Dinner venue at 18:30, and from the Congress Dinner venue back to the Congress venue at 22:00.

Address by Guest of Honour
Koh Poh Koon, Senior Minister of State for Health and Manpower, Singapore

Date: 7 March 2026
Time: 09:00 - 09:15
Venue: Level 3, Laguna Ballroom, Dusit Thani Laguna, Singapore
Dress Code: Formal

Gold Sponsors

Amazon Web Services (Booth No: C02)

Since 2006, Amazon Web Services has been the world's most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 114 Availability Zones within 36 geographic regions, with announced plans for 16 more Availability Zones and five more AWS Regions in Chile, New Zealand, the Kingdom of Saudi Arabia, Taiwan, and the AWS European Sovereign Cloud. Millions of customers including the fastest-growing startups, largest enterprises, and leading government agencies trust AWS to power their infrastructure, become more agile, and lower costs.

To learn more about AWS, visit www.aws.amazon.com

illumina (Booth No: B02)

At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Our microarrays also provide accurate, high-throughput genotyping for a range of applications.

Through innovation and collaboration, we have developed comprehensive genomic profiling tools that help investigators identify biomarkers, describe tumor biology, and inform therapy selections. The opportunity to transform tumor profiling with innovative assays, new companion diagnostics, and liquid biopsy tools inspires us to push the boundaries of what is possible and drive innovation.

To learn more about Illumina, visit www.illumina.com

PacBio

Pacific Biosciences (PacBio) (Booth No: B01)

Pacific Biosciences (PacBio) is a global leader in long-read sequencing and multi-omics technologies that empower scientists to explore the full complexity of genomes, transcriptomes, and epigenomes with unmatched accuracy. PacBio's innovations in Single Molecule, Real-Time (SMRT®) sequencing are advancing discoveries in hereditary cancer research, population genomics, and microbiome science through comprehensive and highly accurate data generation.

At the core of PacBio's technology is HiFi sequencing, which delivers long reads with exceptional accuracy (>99.9%), enabling researchers to resolve complex genomic regions, structural variants, and haplotypes that are often missed by short-read technologies. These capabilities are particularly valuable in hereditary tumour research, cancer gene discovery, and pharmacogenomics (PGx) studies, where complete and phase-resolved genomic information is essential for understanding genetic mechanisms of disease susceptibility.

PacBio technologies are used by leading research institutes and national genomics programs worldwide, including across the Asia Pacific region, where scientists are leveraging HiFi long-read sequencing to generate comprehensive and high-confidence genomic data for translational research and scientific discovery.

Our mission is to enable researchers to see biology in its truest form delivering the accuracy and completeness needed to advance human understanding.

To learn more about PacBio, visit www.pacb.com

Oxford Nanopore Technologies

Oxford Nanopore Technologies (Booth No: C01)

Oxford Nanopore Technologies' vision is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Company has developed a new generation of nanopore-based sensing technology that is currently used for information-rich, rapid, accessible and affordable DNA and RNA analysis. The platform is also being developed for the analysis of proteins and metabolites. The technology is being used in more than 125 countries to understand the biology of humans, plants, animals, bacteria, viruses and environments, as well as a range of diseases including cancer.

Disclaimer: Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

Find out more: www.nanoporetech.com

Lanyard Sponsor

Ambry Genetics®

Ambry Genetics

With over 20 years of scientific innovations and discoveries, Ambry is an industry leader enabling healthcare professionals to confidently make informed care decisions with their patients by providing them with advanced genetic testing solutions.

At Ambry, people are at the center of our advancements, which starts with our own team. Recognized as an award-winning and outstanding place to work, we maintain a commitment to fostering diverse knowledge and perspectives to drive meaningful collaboration and help us all strive toward better health.

Find out more: www.ambrygen.com.

Exhibitors

Gene Solutions (Booth No: B03)

Gene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging multi-omics, NGS, and AI, the company offers a portfolio including multicancer early detection (SPOT-MAS) and comprehensive tumor profiling with ctDNA monitoring (K-TRACK, K-4CARE). Gene Solutions operates CAP-accredited NGS laboratories and has delivered millions of genetic tests worldwide since 2017.

For more information, visit www.genesolutions.com

Merck & Co., Inc. (Booth No: A01)

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

For more information, please visit www.msd.com

NovogeneAIT (Booth No: A02)

NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. It is formed as a strategic joint venture between Novogene and AITbiotech, a Singapore biotech Company in 2016. With an unwavering commitment to delivering high-quality, swift, and cost-effective omics solutions, NovogeneAIT Genomics has grown to become one of the largest NGS service providers in Southeast Asia. It offers a comprehensive suite of multi-omics services encompasses genomics, transcriptomics, single cell/spatial transcriptomics, metagenomics, and proteomics. Operating from our state-of-the-art sequencing center in Singapore, NovogeneAIT is dedicated to advancing genomic research by offering unmatched data quality that empowers researchers across diverse sectors, including healthcare and agriculture, to realize their research goals.

For more information, visit www.novogene.com/amea-en

Promega

Promega Corporation (Booth No: C03)

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. With a strong foundation in molecular biology, Promega enables researchers, clinicians, and diagnostic developers to generate reliable, high-quality data from discovery to clinical application. Promega's portfolio supports key areas of clinical and translational research, including molecular oncology, molecular diagnostics, diagnostic assay development, and clinical assay development services.

In addition to its off-the-shelf solutions, Promega partners with diagnostic and biotechnology organizations through custom and OEM services, supporting assay development and commercialization from concept to market. With cGMP manufacturing, ISO-certified quality systems, and in-house production of the majority of its reagents, Promega delivers scalable, custom formulations, components, and private-label solutions for clinical and molecular diagnostic applications. Together, these capabilities support applications across DNA and RNA analysis, therapeutic development, infectious diseases, and One Health—turning discovery into clinical impact.

Find out more: www.promega.sg

TWIST BIOSCIENCE

Twist Bioscience Corporation (Booth No: A03)

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist manufactures synthetic DNA-based products, including synthetic genes, tools for NGS preparation, and antibody libraries for drug discovery and development.

Find out more here: www.twistbioscience.com

Acknowledgements

Partners

JGHFoundation Journal of Gastroenterology and Hepatology Foundation

Familial Cancer Quarterly Journal on Cancer Genetics

Gold Sponsors

aws

illumina

Oxford Nanopore Technologies

PacBio

Lanyard Sponsor

Ambry Genetics

Exhibitors

GENE SOLUTIONS

MSD

NovogeneAIT

Promega

TWIST BIOSCIENCE

Organised by

ICaN Asia INHERITED CANCERS NETWORK ASIA

Singapore Society of Oncology

Supported by

IAP International Academy of Pathology Singapore Division

SCRS SOCIETY OF COLORECTAL SURGEONS SINGAPORE

SINGAPORE EXHIBITION & CONVENTION BUREAU

Held in

SG singapore Passion Made Possible

Managed by

kenes group singapore